The effects of interferon on cultured cells persistently infected with viruses by Crespi, Madeleine
THE EFFECTS OF INTERFERON ON CULTURED CELLS PERSISTENTLY
INFECTED WITH VIRUSES
Madeleine Crespi, Lie. en Sciences Naturelles (Lausanne),
MSc (Witwatersrand, Johannesburg)
A Thesis Submitted to the Faculty of Medicine 
University of the Witwatersrand, Johannesburg for 
the Degree of Doctor of Philosophy in Medicine
Johannesburg 1986
II
DECLARATION
I hereby declare that this thesis is my own, unaided work.
It is being submitted for the degree of Doctor of Philosophy 
in Medicine in the University of the Witwatersrand, 
Johannesburg. It has not been submitted before for any 
degree or examination in any other University.
Cu? " y ' l —
day of
A B S T R A C T
An investigation was done to examine the role of IFN in 
viral persistence at the cellular level. For this purpose two 
types of persistent infections were chosen. The first type was 
cell lines which contained hepatitis B virus (HBV) DNA (PLC/PRF/5 
and Hep 3B cells) uninfected control hepatoma cells, (Mahlavu,
HA22T and Hep G2 cells) or simian virus 40 (SV40) DNA (C2, C6,
Cll cells) and control uninfected (CV-1 cells). In the second 
type of infection Vero cells persistently infected with SSPE or 
Sendai virus were used.
The aim of this work was to determine what effect IFN had 
in these infections in terms of its antiviral and antiproliferative 
effects; which of the two major IFN-induced pathways, E enzyme 
or protein kinase were induced; whether there were any differences 
in sensitivity to IFN between the DNA and RNA virus persistent 
infections.
None of the cell lines produced endogenous IFN. The anti­
viral effect of IFN was examined by its ability to inhibit 
Sindbis virus replication using a radioimmunoassay system. The 
hepatoma and the CV cells were sensitive to the antiviral effect 
of IFN with low concentration of IFN («£80 IU/ml) inhibiting 
Sindbis virus replication. In Vero cells persistently infected 
with SSPE or Sendai virus a concentration of IFN equal to or 
greater than 1 600 IU/ml inhibited Sindbis virus replication, 
while in control Vero cells a concentration of 4 IU/ml of IFN 
was needed. This resistance appeared within a few passages
of the development of SSPE or Sendai persistent infection. 
Similarly the synthesis of measles virus polypeptides in 
lytically infected Vero cells was inhibited by an IFN concentra­
tion of less than 200 IU/ml, whereas the synthesis of SSPE and 
Sendai virus polypeptides were not affected by a concentration 
of 4 000 IU/ml of IFN.
The antiproliferative effect of IFN was determined by cell
3
counting and H-thymidine incorporation. All hepatoma and CV 
cells with the exception of Hep 3B cells were sensitive to the 
antiproliferative effect of IFN. The growth of control Vero 
cells were also inhibited by IFN whereas in SSPE-Vero and Sendai- 
Vero cells IFN had no inhibitory effect.
The induction of the two main IFN-induced enzyme pathways, 
the E enzyme and the protein kinase, was investigated.
The E enzyme was activated by IFN in all hepatoma and CV 
cells, from two-fold in Hep G2 cells to thirty-eight-fold in 
Cll cells. While increases in E enzyme levels were detected in 
SSPE and Sendai-Vero cells, these increases were regarded as 
being insignificant as the basal levels were very low. The 
activation of the ribonuclease F, determined by the inhibition
3
of H-leucine incorporation after introduction of 2-5 A into 
the cells, was variable, being activated in all cell lines with 
the exception of the PLC/PRF/5, Hep 3B and Hep G2 cells.
The activation of the protein kinase in extracts of cells, 
pretreated with IFN, was determined by the phosphorylation of 
«<-eIF-2 subunit in the presence of dsRNA. Using a positive 
L-cells control extract it was shown that IFN did not activate 
the protein kinase in any of the cell lines studied.
VMajor differences between the two DNA persistent infections 
and the two RNA persistent infections were found. No correlation 
was found between the presence of HBV or SV40 persistent infections 
and the sensitivity of the cell lines to IFN. On the other hand 
both the SSPE and Sendai virus persistent infections were 
resistant to the antiviral and antiproliferative effect of IFN.
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FIG. 35. Electrophoresis of eIF-2 preparations used. 
Gels were stained with Coomassie blue.
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FIG. 36. Autoradiogram showing the effect of IFN on 
the protein phosphorylation of L-cells.
L-cell extracts from cells treated in the 
presence or absence of IFN were incubated
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for 30 min in the presence or absence of 
dsRNA (1 pg/ml), eIF-2 (2 pg) (Batch A) in 
buffer containing ATP-^P. The extracts were 
then resuspended in dissociation buffer, run 
on SDS-PAGE and the gel fluorographed. Un­
treated cells (lanes 1-4), treated with 
muIFN (200 IU/ml) (lanes 5-8), treated 
with mock IFN (lanes 9-12).
FIG. 37 Autoradiogram showing the effect of IFN on 
the protein phosphorylation of L-cells.
L-cell extracts from cells treated in the 
presence or absence of IFN were incubated 
for 30 min in the presence or absence of 
dsRNA (1 pg/ml), eIF-2 (2 pg) (Batch B) in 
buffer containing ATP-^P. The extracts 
were then resuspended in dissociation buffer, 
run on SDS-PAGE and the gel fluorographed. 
Untreated cells (lanes 1-4), treated with 
muIFN (lanes 5-8).
FIG. 38. Autoradiogram of extracts of L-cells pretreated
with muIFN (200 IU/ml) and then incubated in
the presence of different concentrations of
eIF-2. Extracts were incubated for 30 min
in the presence of dsRNA (1 pg/ml), of
different concentrations of eIF-2 (Batch A)
32in buffer containing ATP- P. The extracts 
were then resuspended in dissociation buffer, 
run on SDS-PAGE and the gel fluorographed. 
Treated with eIF-2 (5 pg) (lane 1), eIF-2 
(2.5 pg) (lane 2), eIF-2 (2 pg) (lane 3) 
without eIF-2 (lanes 4, 5). The presence 
of -< and JJ-eIF-2 are indicated.
FIG. 39. Autoradiogram showing the effect of IFN on 
the protein phosphorylation of extracts of 
PLC/PRF/5 cells. Extracts from cells treated
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in the presence or absence of IFN (200 IU/ml) 
were incubated for 30 min in the presence or 
absence of dsRNA (1 jjg/ml), of eIF-2 (2 jug) 
(Batch A) in buffer containing ATP-^P.
The extracts were then resuspended in 
dissociation buffer, run on SDS-PAGE and the 
gel fluorographed. L-cell extracts (lanes 
1-4), PLC/PRF/5 cell extracts (lanes 5-12).
FIG. 40. Autoradiogram showing the effect of IFN on 
the protein phosphorylation of extracts of 
Mahlavu cells. Extracts from cells treated 
in the presence or absence of IFN (200 IU/ml) 
were incubated for 30 min in the presence or 
absence of dsRNA (1 |jg/ml), of eIF-2 (2 jug) 
(Batch A) in buffer containing ATP-^P. The 
extracts were then resuspended in dissociation 
buffer, run on SDS-PAGE and the gel fluoro- 
graphed. L-cell extracts (lanes 1-4),
Mahlavu cell extracts (lanes 5-12).
FIG. 41. Autoradiogram showing the effect of IFN on 
the protein phosphorylation of extracts of 
Hep 3B cells. Extracts from cells treated 
in the presence or absence of IFN (200 IU/ml) 
were incubated for 30 min in the presence or 
absence of dsRNA (1 jjg/ml), of eIF-2 (2 |ug) 
(Batch B) in buffer containing ATP-^P. The 
extracts were then resuspended in dissociation 
buffer, run on SDS-PAGE and the gel fluoro- 
graphed. L-cell extracts (lanes 1-4), Hep 
3B cell extracts (lanes 5-12).
FIG. 42. Autoradiogram showing the effect of IFN on 
the protein phosphorylation of extracts of 
Hep G2 and HA22T cells. Extracts from cells 
treated in the presence or absence of IFN 
(200 IU/ml) were incubated for 30 min in the
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presence or absence of dsRNA (1 jjg/ml), of
eIF-2 (2 ug) (Batch B) in buffer containing 
32ATP- P. The extracts were then resuspended
in dissociation buffer, run on SDS-PAGE and
the gel fluorographed. Hep G2 cell extracts
(A), HA22T cell extracts (B). L-cell
extract (lane 9). 116
FIG. 43. Autoradiogram showing the effect of IFN on
the protein phosphorylation of extracts of
CV-1 cells. Extracts from cells treated in
the presence or absence of IFN (200 IU/ml)
were incubated for 30 min in the presence
or absence of dsRNA (1 jjg/ml), of eIF-2
(2 Lg) (Batch B) in buffer containing 
32ATP- P. The extracts were then resuspended
in dissociation buffer, run on SDS-PAGE and
the gel fluorographed. L-cell extracts
(lanes 1-4), CV-1 cell extracts (lanes 5-12). 117
FIG. 44. Autoradiogram showing the effect of IFN on 
the protein phosphorylation of extracts of 
C2, C6 cells. Extracts from cells treated 
in the presence or absence of IFN (200 IU/ml) 
were incubated for 30 min in the presence or 
absence of dsRNA (1 pg/ml), of eIF-2 (2 pg)
(Batch B) in buffer containing ATP-22P. The 
extracts were then resuspended in dissociation 
buffer, run on SDS-PAGE and the gel fluoro- 
graphed. C2 cell extracts (A), C6 cell ex­
tracts (B), L-cell extracts (lane 9). 118
FIG. 45. Autoradiogram showing the effect of IFN on 
the protein phosphorylation of extracts of 
Cll cells. Extracts from cells treated in the 
presence or absence of IFN (200 IU/ml) were 
incubated for 30 min in the presence or 
absence of dsRNA (1 pg/ml), of eIF-2 (2 pg)
page
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(Batch B) in buffer containing ATP-^P.
The extracts were then resuspended in
dissociation buffer, run on SDS-PAGE and
the gel fluorographed. L-cell extracts
(lanes 1-4), Cll cell extracts (lanes 5-12). 119
FIG. 46. Autoradiogram showing the effect of IFN on
the protein phosphorylation of extracts of
Vero cells. Extracts from cells treated in
the presence or absence of IFN (200 IU/ml)
- were incubated for 30 min in the presence
or absence of dsRNA (1 pg/ml), of eIF-2
(2 Ug) (Batch A) in buffer containing 
1 32ATP- P. The extracts were then resuspended
in dissociation buffer, run on SDS-PAGE and
the gel fluorographed. L-cell extracts
(lanes 1-4), Vero cell extracts (lanes 5-12). 120
FIG. 47. Autoradiogram showing the effect of IFN on 
the protein phosphorylation of extracts of 
SSPE-Vero cells. Extracts from cells treated 
in the presence or absence of IFN (200 IU/ml) 
were incubated for 30 min in the presence or 
absence of dsRNA (1 Jjg/ml), eIF-2 (2 pg)
(Batch A) in buffer containing ATP-^P. The 
extracts were then resuspended in dissociation 
buffer, run on SDS-PAGE and the gel fluoro­
graphed. L-cell extracts (lanes 1-4), SSPE- 
Vero cell extracts (lanes 5-12). 121
FIG. 48. Autoradiogram showing the effect of IFN on the
protein phosphorylation of extracts of Vero
and Sendai-Vero cells. Extracts from cells
treated in the presence or absence of IFN
(200 IU/ml) were incubated for 30 min in the
presence or absence of dsRNA (1 Jjg/ml),
eIF-2 (2 Lg) (Batch B) in buffer containing 
32 'ATP- P. The extracts were then resuspended
page
in dissociation buffer, run on SDS-PAGE
and the gel fluorographed. Vero cell extracts
(A), Sendai-Vero cell extracts (B).
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FIG. 49. Autoradiogram showing the effect of IFN on
the protein phosphorylation of extracts of 
Sendai-Vero cells. Extracts from cells 
treated in the presence or absence of IFN 
(200 IU/ml) were incubated for 30 min in the 
presence or absence of dsRNA (1 jug/ml),
containing
in dissociation buffer, run on SDS-PAGE and 
the gel fluorographed. Sendai-Vero cell 
extracts (A), L-cell extracts (B).
page
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resuspended
1CHAPTER 1 
INTRODUCTION
Interferon (IFN) is by definition an inducible protein secreted 
by cells that induces an antiviral state in other cells (Stewart,
1979; Pestka and Baron, 1981). IFN was discovered by Isaacs 
and Lindenman (1957) who found that, upon exposure to heat-inactivated 
influenza virus, chicken chorioallantoic membranes released a 
substance into the surrounding fluid that, when added to the 
culture medium of other cells, inhibited the replication of active 
influenza virus. Since it interfered with virus replication,
Isaacs and Lindenman called the substance IFN. Most of the cell 
types from a large variety of vertebrates can produce IFN (Lengyel, 
1982; Sen, 1982). IFN is induced by a variety of agents which 
include all the major virus groups, protozoa, bacteria, fungal 
products and mitogens as well as natural and synthetic nucleic 
acids (Stewart, 1979; Pestka and Baron, 1981; Baron et al.,
1985). Under normal growth conditions IFN concentrations are 
below detectable levels in most organs and cell cultures (Lengyel, 
1982; Sen, 1982).
A concentration of 3x 10" *4 M of IFN may impair virus replica­
tion; therefore, IFN is one of the most potent biological agents 
known in cell culture (Sen, 1982). IFN is responsible for 
numerous other effects besides its antiviral activity. It may 
change the motility, proliferation or differentiation of cells 
(Stewart, 1979; Sen, 1982; Taylor et al., 1984); it may also 
affect various immunological processes such as antibody response, 
delayed hypersensitivity, graft rejection, enhancement of the
2expression of certain surface antigens, recruitment of natural 
killer cells and activation of macrophages (Stewart, 1979; Hooks 
and Dietrick-Hooks, 1982). IFN also has an antitumour effect in 
experimental animal systems and against certain human tumours 
such as laryngeal papillomas and lymphomas (Stewart, 1979;
Czarniecki and Friedman, 1982; Malpas, 1983). In the late 1970's 
human IFN became one of the "wonder" drugs due to its antitumour 
and antiviral effects.
It is the purpose of this chapter to review the characteristics 
of human IFN, the main metabolic pathways stimulated in in-vitro 
systems and IFN's importance in persistent viral infections.
1.1. BRIEF REVIEW OF HUMAN IFN
1.1.1. Natural IFNs
Three antigenically distinct types of human IFN have been 
described: leucocyte (<*)> fibroblast (ji) and immune (y).
Their differences depend on the type of cell from which they 
originate and their inducing conditions (Pestka and Baron, 1981) 
(Table 1).
IFNs of the oc-type are products of a multigene family 
sharing up to 80% homology (Collins, 1984; Gren et al., 1984). 
Whenever leucocytes are induced to produce o<-IFN, a number of 
these genes are expressed resulting in a preparation which contains 
a mixture of different o<-subtypes (Gren et al., 1984). In contrast 
to <*-IFN, p-IFN seems to have only one or two genes (Weissenbach 
et a 1., 1980; 'Collins, 1984). The genes coding for the o(-IFNs 
and for ^ -IFN show about 35% homology and are located on chromo­
3some 9 (Collins, 1984). Chromosomes 2 and 5 have also been shown 
to contain | M F N  genes (Collins, 1984). - -The gene coding for 
y-IFN, which is located on chromosome 12, shows little homology 
with the genes of £ and oC-IFNs. The y-IFN gene contains two 
introns; introns are absent in the other IFN genes (Gray et al., 
1982; Collins, 1984).
The main characteristics of and y-IFN are shown in
Table 1.
1.1.2. Lymphoblastoid IFN
One of the human IFNs used for experimental study in vivo and 
in vitro is lymphoblastoid IFN. The shortage of o<,-IFN from 
human leucocytes prompted research into producing IFN from trans­
formed human cell lines (Finter and Fantes, 1980, 1984). Strander 
et al. (1975) and Finter and Fantes (1980) produced human IFN 
from the human lymphoblastoid cell line called "Namalwa". Namalwa 
cells are B lymphocytes containing the Epstein Barr virus (EBV) 
genome, and were isolated from a patient with Burkitt's lymphoma 
(Klein et al., 1972).
Namalwa cells produce large amounts of IFN after induction 
with Sendai or Newcastle disease virus (NDV) (Finter and Fantes, 
1980, 1984). Lymphoblastoid IFN“prdduced by Namalwa cells consists 
of 60 to 70% ot-lFN and 10 to 20% £ -IFN (Havell et al., 1977; 
Finter and Fantes, 1984). This IFN has been shown to induce 
antiviral activity and to inhibit cell growth in a number of 
cell types (Gresser et al., 1974; Gewert et al., 1981, 1983;
Tovey et al., 1982).
TABLE 1. The properties of the three major groups of IFN
produced in human cells
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IFN TYPE e r
INDUCING
AGENT
dsRNA 
Viruses 
Mitogens 
B Lymphocytes 
Bacteria
dsRNA 
Viruses 
Inhibitors of 
RNA and 
protein 
synthesis
Foreign Antigens 
Mitogens 
T Lymphocytes
MAJOR 
PRODUCER 
CELL TYPE
Leucocytes 
B Lymphocytes 
Macrophages
Fibroblasts 
Epithelial cells 
Myeloblasts 
Lymphoblasts
T Lymphocytes
MOLECULAR 
WEIGHT (MW)
15-23 OOO 20-23 000 20-25 000
No. AMINO ACIDS 
IN PRIMARY 
PROTEIN
165-166 166 166
GENES 13 2 1
INTRONS no no yes
CHROMOSOMAL
LOCATION
9 2, 5, 9 12
ISOELECTRIC 
POINT (pi)
5.7-7.8 6.5 8.6
PROPERTIES
Stable at 
pH2
Stable with 
SDS
Non glycosy­
lated
Stable at 
pH2
Stable with 
SDS
Glycosylated
Unstable at 
pH2 and to 
SDS
Glycosylated
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Collins, 1984
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51.1.3. Recombinant IFN
Using recombinant DNA techniques the genes of human t f , p ,  
and Y'-IFN have been cloned into Escherichia coli, yeast and 
cultured cells (Nagata et al., 1980; Weissenbach et al., 1980; 
Hitzeman et al.> 1981; Mory et al., 1981; Gray et al., 1982; 
Kingsman and Kingsman, 1983; Pestka, 1983; Devos et al., 1984; 
Arakawa et al., 1985). These recombinant (rec) IFNs have been 
shown to produce an antiviral and antiproliferative effect in 
vitro (Samuel and Knutson, 1981; Gray et al., 1982; Pestka, 1983; 
Czarniecki et al., 1984; Devos et al., 1984; Overall et al.,
1984; Arakawa et al., 1985). Comparison of the physicochemical 
and biological properties of o(-IFNs produced by human leuco­
cytes and E. coli have shown that they are similar and have 
analogous properties; the main difference is that rec «(-IFN 
preparations contain only one o<-IFN subtype, while the naturally- 
derived <<-IFN contains different subtypes (Stewart et al., 1980; 
Nagata et al., 1980; Kingsman and Kingsman, 1983).
1.2. OVERVIEW OF THE IFN-CELL SYSTEM
A common pathway of IFN production in different type of cells 
has been proposed. IFN genes that are normally switched off 
are activated by certain inducers and the genes transcribed (Burke,
1983). The mRNAs are transported to the cytoplasm where they 
are translated in the rough endoplasmic reticulum, and the resultant 
proteins are glycosylated ( *-IFN excepted) and discharged into 
the extracellular milieu (Stewart, 1979; Burke and Shuttleworth,
61984). The amount of IFN produced has been shown to be directly 
proportional to the amount of IFN mRNA present (Morser et al.,
1979) and can be enhanced by butyrate, 5-bromodeoxyuridine or 
by IFN pretreatment (priming phenomenon) (Adolf and Swetly, 1979; 
Stewart, 1979; Johnston, 1980). IFN production lasts for only 
a few hours following induction; the cause of the switch off 
of IFN production may be degradation or inactivation of the mRNA 
(Burke, 1983).
After liberation into the extracellular environment IFN 
recognizes and then binds to cells which possess specific IFN 
membrane receptors (Stewart, 1979). Studies of the binding of 
various IFNs to cells have led to the conclusion that there are 
separate receptors for o( and y'-IFN (Branca and Baglioni, 1981) 
while £-IFN has been shown to share the same receptors as o(-lFN 
(Branca and Baglioni, 1981). Some binding competition has been 
found between J2 and y-IFN (Thompson et al., 1985).
The nature of IFN receptors is still obscure, a ganglioside 
and a protein structure having been postulated for the and 
p-IFN receptors (Vengris et al., 1976; Besanfon and Ankel, 1977; 
Gupta et al., 1984). Recently chromosome 21 has been shown to be 
responsible for the coding of o< and JJ-IFN receptors (Raziuddin 
et al., 1984; Smith-^Johanssen et al., 1984). The gene for the 
Y’-IFN receptor has been located on chromosome 6 (Rashidbaigi et 
aU, 1986).
Little is known of the events following receptor binding. 
Branca et al. (1982) have shown that after binding, human ^-IFN 
is internalized and degraded. However, the need for internaliza­
tion to produce a biological effect is still controversial
7(Branca et al., 1982; Yonehara et al., 1983). It has been 
proposed that events at the cell membrane trigger signals to the 
nucleus which lead to the transcription of mRNA coding for the 
proteins responsible for mediating the effects of IFN (McMahon 
and Kerr, 1983; Smith-Jotianssen et al., 1984). Cyclic AMP 
may also be involved in the transcription of certain proteins 
(Kerr et al., 1984). After IFN treatment, newly synthetized mRNA 
and proteins have been detected and these proteins are presumed 
to be responsible for the antiviral and antiproliferative effects 
(Lengyel, 1982; Smith-Johanssen et al., 1984; Kerr et al., 1984).
1.3. THE IN-VITRO EFFECTS OF IFN
Two effects produced by IFN in cells have been extensively 
studied. Firstly, the inhibition of cell proliferation (anti­
proliferative effect) and secondly, the ability of IFN to protect 
cells against virus infection. These two effects have been shown 
to be separate and major differences exist in the mechanisms 
used (Taylor-Papadimitriou et al., 1985). The fact that long 
exposure to IFN and higher levels of IFN are required for effective 
growth inhibition in comparison to the lower levels necessary for 
the establishment of an antiviral state suggests that the receptor 
interactions leading to the antiviral and antigrowth effects may 
not be identical (Taylor-Papadimitriou, 1980; Taylor-Papadimitriou 
et al., 1985).
1.3.1. The antiproliferative effect
The cellular mechanism(s) induced by IFN which produce the
8antiproliferative effect are still unknown (Sreevalsan, 1984).
As the antiviral effect of IFN is mediated by more than one - 
mechanism, the antiproliferative effect is probably also mediated 
by more than one mechanism (Sreevalsan, 1984).
IFN has been shown to produce an antiproliferative effect 
in a wide range Of cell types (Taylor et al., 1984). The anti­
proliferative effect is mediated by receptors on the cell membrane 
(Kuwata et al., 1976; Taylor-Papadimitriou, 1980) and has been 
studied by either observing a reduction in cell number, or by a 
decrease in macromolecular synthesis where incorporation of radio­
active precursors of DNA, RNA or proteins is used as a method of 
assay (Hilfenhaus et al., 1976; Fuse and Kuwata, 1977; Taylor 
et al., 1984).
IFN has been shown to act on the cell cycle by inhibiting the 
cell's entry into the S phase and by prolonging the Gj and S + G2 
phases (Macieira-Coelho et al., 1971; Mataresi and Rossi, 1977; 
Sokawa et al., 1977).
The sensitivity of cells to the antiproliferative effect of 
IFN ranges from very sensitive to resistant depending upon the 
cell type studied (Taylor et al., 1984). Previously it was thought 
that transformed cells were more sensitive to the anticellular 
effect of IFN than non-tumour derived cells (Strander and Einhorn,
1977), but this is not the case.- “For^example, X-ray transformed 
cells derived from C3H fibroblasts were less inhibited than the 
non-transformed cells (Brouty-Boye et al., 1979). Various 
lymphoblastoid cell lines have been compared regarding their 
sensitivity to the antiproliferative effect of IFN and have been 
shown to be inhibited to differing degrees (Hilfenhaus et a 1.,
1977).
9The sensitivity of cells to the antiproliferative effect of 
IFN also depends on the type of IFN used (Taylor et al., 1984). 
of and P-IFN showed a similar antiproliferative effect when 
used in Daudi cells (Hilfenhaus et al., 1976). In contrast,
Borden et al. (1982) have compared the antiproliferative actions 
of o( and £-IFN in a number of cell lines and demonstrated that 
some cells were more sensitive to J5-IFN than o c-ifn. y-IFN 
produced a significant cellular inhibition in HeLa and U-amnion 
cells while Daudi cells were insensitive (Tomita et al., 1982a;
Rubin et al., 1983). Cloned *-IFNs also appeared to act differently 
on the same cell line, some producing a greater anticellular 
activity than others (Fish et al., 1983).
The timing and duration of IFN treatment have also been 
shown to produce variations in IFN's effects even when the same 
cell system was used (Taylor et al., 1984). Daudi cells reacted 
less if IFN was added to actively growing cells (Horoszewicz et 
al., 1976) and an inhibitory effect on DNA synthesis could be 
seen only when IFN was added in the late phase or early S phase 
in RSA cells (Fuse and Kuwata, 1977). The duration of treatment 
required for IFN to initiate an antiproliferative action also 
varied considerably in different cell systems. L-cells needed a 
minimum of 8 hours (h) of incubation with IFN (Gresser et al.-,
1970) while murine osteogenic sarcoma required more than 24 h 
before the antiproliferative effect was noted (Glasgow et al.,
1978).
Gresser et al. (1970) found that in L 1210 and Ehrlich 
ascites cells IFN acted better when it was added to a lower con­
centration of cells and when a low serum concentration in the
10
growing medium was used.
1.3.2. The antiviral effect
As with the antiproliferative effect, the antiviral effect 
is mediated by receptors on the cell membrane (Smith-Johanssen 
et al., 1984). The antiviral action of IFN involves the induction 
and/or activation of certain cellular proteins which block virus 
replication, notably the synthesis of viral components and/or 
their assembly into new virus particles. The degree of inhibition 
varies from virus to virus and often is related to the dose of 
IFN and to the multiplicity of infection (Stewart, 1979).
Different assays have been established to measure the anti­
viral activity of IFN. The more common of these antiviral assays 
are the inhibition of viral cytopathic effect, plaque reduction, 
virus yield reduction, radioimmunoassays and immunofluorescence 
assays (Falcoff et al., 1973; Grossberg et al., 1984). Antiviral 
activity is also used to standardize different IFN preparations.
The preparations are calibrated against reference standards and 
the concentration or titer of IFN is given as international units 
(IU) per milliliter of sample, one IU being the reciprocal of 
the dilution producing a 50% reduction in viral yield.
The mode of action of IFN7 varies with different virus. In 
fact, IFN may interfere with any stage of viral replication such 
as adsorption, penetration, uncoating, transcription, translation, 
assembly or release of the virus. Early experiments with infectious 
viruses suggested that IFN-treated cells were able to adsorb 
viruses normally, but later it was found that IFN induced a change
11
in the cell membrane suggesting that membrane changes may also play 
a role in inhibiting the adsorption and penetration of viruses 
(Stewart, 1979).
IFN has been shown to inhibit the penetration and uncoating 
of murine leukemia virus (MuLV) (Aboud et al., 1980; Salzberg et al., 
1983a). Inhibition of early viral transcription has been observed 
with vesicular stomatitis virus (VSV) and simian virus 40 (SV40);
IFN inhibited VSV RNA polymerase activity and the transcription of 
early mRNA of SV40 (Marcus et al., 1971; Oxman and Levin, 1971;
Yamamoto et al., 1975; Revel, 1979).
The results of numerous studies concerning the effect of IFN 
on protein synthesis have shown that inhibition of translation is 
the major mechanism mediated by IFN (Marcus and Salb, 1966; Stewart,
1979). Depending on the conditions of cell growth, IFN dose and 
virus multiplicity, both host and viral or exclusively viral protein 
synthesis is inhibited (Kerr et al., 1984). This mechanism whereby 
viral protein synthesis can be inhibited may involve two minor path­
ways independent of double-stranded (ds) RNA or two major pathways 
dependent on dsRNA. In the minor pathways IFN acts directly on tRNA 
and mRNA. After IFN treatment it has been shown that cells lose 
their ability to translate mRNA and this may be overcome by adding 
tRNA (Gupta et al., 1974). This suggests that IFN may act by changing 
endogenous tRNA so it cannot accept-newly made amino acTdsv Different 
species of tRNA were found necessary to restore translation in cell- 
free lysates (Falcoff et al., 1976; Mayr et al., 1977). The loss of 
aminoacylation activity of leucine, lysine and serine tRNAs was much 
faster in extracts of IFN-treated cells than in extracts of control
cells (Sen et al., 1976). The inactivation of tRNA may be a consequence
• •
of an increase in the level of 2-5 oligoadenylic acid (2-5 A) phospho­
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diesterase upon IFN treatment; this enzyme, in fact, can remove the 
CCA terminus from tRNAs and inhibit tRNA aminoacylation (Lengyel,
1982; Sen, 1982).
IFN acts on mRNA by inhibiting cap methylation which is 
responsible for the binding of mRNA to ribosomes. Inhibition of cap 
methylation by IFN has been observed in reovirus and in VSV-infected 
cells (Sen et al., 1977; de Ferra and Baglioni, 1981). This impair­
ment is due to the presence of an inhibitor of cap methylation in 
the extracts of IFN-treated cells. This inhibitor is very labile at 
37°C and has been characterized only by its ability to impair cap 
methylation (Sen, 1982).
Inhibition of mRNA translation by IFN can also be mediated by 
the dsRNA-dependent pathways (Kerr et al., 1974, 1976). DsRNA is 
usually produced during replication of most viruses and has been 
shown to be an IFN inducer and a trigger for initiating the inhibition 
in IFN-treated cells (Stewart, 1979; Lengyel, 1982; Sen, 1982).
The two IFN-activated pathways dependent on dsRNA are:
1) cAMP independent protein kinase
2) 2'-5' oligo A synthetase (E enzyme) (Kerr et al., 1984).
The two systems are independent of each other, although both need 
ATP and dsRNA (Farrel et al., 1978). Both enzymes are present 
constitutively in a wide variety of cells and'ctissues, but their 
levels increase in response to IFN (Kerr et al., 1984).
1.3.2.1. Protein kinase
Treatment of animal cells with IFN results in the induction 
of a dsRNA-dependent protein kinase which catalyzes the phosphoryla­
tion of the endogenous ribosome associated proteins, PI and the 
c i-subunit of eukaryotic initiation factor 2(*-eIF-2), and 
histones (Kimchi et al., 1979a).
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PI has a MW of 67-72 000 in human cells while the MW in 
murine cells is 65-68-000 (Lebleu et al., 1976; Kimchi et al., 
1979a; Samuel, 1979a). There is a controversy regarding the 
function and identity of PI. PI is thought to be the protein 
kinase itself or part of the enzyme as purification studies have 
failed to separate PI from dsRNA-dependent protein kinase activity 
(Kimchi et al., 1979a; Berry et al., 1985). The MW of the 
protein kinase has been shown to be comparable with the MW 
observed for phosphorylated PI (Berry et al., 1985) and PI contains 
a dsRNA-dependent ATP binding site (Bischoff and Samuel, 1985). 
However, by using monoclonal antibodies specific for PI, it has 
been shown that a clean PI preparation lacked the property of 
phosphorylation of itself or exogenous histones, suggesting that 
PI and the protein kinase are two different entities (Laurent et 
al., 1985; Penn and Williams, 1985). Recently Galabru and 
Hovanessian (1985) have shown that the dsRNA-dependent protein 
kinase is a 100 000 MW complex of two IFN-induced subunits each 
having ATP binding sites; a 48 000 MW and a 68 000 MW subunit.
The 48 000 protein is most probably involved with the phosphoryla­
tion of 68 000 protein which in turn becomes active and phos- 
phorylates the exogenous substrate eIF-2 and histones (Galabru 
and Hovanessian, 1985).
The second endogenous protein phosphorylated by the protein 
kinase has been shown to be the * -subunit of eIF-2 which has a 
MW of 35-37 000 daltons (Lebleu et al., 1976; Zilberstein et al., 
1976). The phosphorylation of ©<-eIF-2 inhibits the formation 
of the met-tRNAp-40s ribosome complex, one of the first steps in 
mRNA translation (Jagus et al., 1981). This inhibition has
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previously been proved in vitro by using ribosomal supernatant 
of rabbit reticulocyte lysate which contai-nsan ATP-dependent 
protein kinase which phosphorylates o(-eIF-2 (Jagus et al., 1981). 
Exogenous added eIF-2 has also been shown to overcome the impair­
ment of protein synthesis produced by an activated ribosomal 
preparation of ascites cells pretreated with IFN (Farrel et al.,
1978).
Evidence has been provided that the rate and extent of 
induction of the antiviral state in cells by IFN correlates with 
IFN's ability to induce the protein kinase system. Removal of 
IFN from the medium of L-cells infected with reovirus or VSV 
produced a corresponding increase in virus yield and a decrease 
in the level of the IFN-induced protein kinase (Samuel and 
Knutson, 1982a). Phosphorylation of PI and «.-eIF-2 was also 
observed in the HeLa cells after infection with reovirus and 
encephalomyocarditis virus (EMCV) and possibly the activation of 
the kinase was responsible for the inhibition of viral and cellular 
protein synthesis (Nilsen et al., 1982; Rice et al., 1985).
Only viral or synthetic dsRNA can activate the IFN-induced 
protein kinase (Lebleu et al., 1976), but this activation is 
minimal if the kinase has not previously been stimulated by IFN 
(Zilberstein et al., 1976; Samuel, 1979b). All types of IFN 
can induce the protein kinase and-an increase of activity of five 
to ten-fold has been observed (Lebleu et al., 1976; Samuel, 1979b; 
Hovanessian et al., 1980; Sen, 1982). The ability of IFN to 
stimulate the protein kinase varies in cells. An increased level 
of protein kinase following IFN treatment can be detected after 
3 h in L-cells (Kimchi et al., 1979b) whereas in HeLa cells the
15
kinase level only increased after 10 h (Baglioni et al., 1979).
In RD-114 cells, persistently infected with RD-114 retrovirus, 
and in human fibroblasts, IFN is able to activate the E enzyme 
but not the protein kinase (Meurs et al., 1981; Holmes and Gupta, 
1982; Sen et al., 1983). In L-cells, HeLa, human amnion U cells 
and NIH-3T3 cells IFN activated the protein kinase (Baglioni 
et al., 1979; Kimchi et al., 1979a; Samuel, 1979b; Epstein et 
a k , 1981).
Lack of protein kinase activity may be due to phosphoprotein 
phosphatases. A phosphoprotein phosphatase has been partially puri­
fied and- it acts on the phosphorylated PI and 0(,-eIF-2; dsRNA was 
thought to stop the phosphatase degradation but it has been shown 
that the enzyme is independent of dsRNA (Kimchi et al., 1979a; 
Epstein et al., 1980; Samuel and Knutson, 1982b).
The stimulation of the protein kinase by IFN can be assayed 
in vitro by the phosphorylation of PI and of o(-eIF-2 in IFN- 
treated cell extracts in the presence of dsRNA. The phosphorylated 
PI and oC-eIF-2 are then detected by sodium dodecyl sulphate (SDS) 
polyacrylamyde gel electrophoresis (PAGE) followed by auto­
radiography (Lebleu et al., 1976; Zilberstein et al., 1976;
Farrel et al., 1978).
1.3.2.2. 2*-5' oligo A system
The other major system stimulated by IFN is the 2'-5' oligo 
A system which involves three enzymes: the E enzyme which 
synthesizes 2-5 A, the 2-5 A dependent endonuclease (ribonuclease
16
F or L) and 2-5 A phosphodiesterase which degrades 2-5 A to ATP 
or AMP (Fig. 1).
Constitutive levels of all of these enzymes are present in 
a variety of cells and tissues (Kerr et al., 1984). The level of 
the first enzyme usually increases 10 to 10 000-fold in response 
to IFN while relatively minor increases of less than five-fold 
are normally observed in the other two enzymes (Kerr et al.,
1984). Through the activation of the 2-5 A system IFN acts 
again on the protein synthesis mechanism by cleaving cellular 
and viral RNA (Nilsen et al., 1980).
E enzyme
The E enzymes from both mouse and human cells have been 
purified to homogeneity and these have been shown to have MWs of 
105 000 and 100 000 respectively (Dougherty et al., 1980; Yang 
et al., 1981). Lately two groups have demonstrated the presence 
of at least two E enzymes (Revel et al., 1982; St. Laurent et al., 
1983). St. Laurent et al., (1983) using IFN-treated Ehrlich 
ascites tumour cells, found one E enzyme fraction (85-100 000) 
predominantly in the cytoplasm and another fraction (20-30 000) 
mainly in the nucleus. Revel et al. (1982) reported two E enzymes 
in human cells, one of 60 000 MW and the other of 20-30 000 MW.
In the intact cells the two E enzymes may regulate different 
events, depending on whether the activating dsRNA is nuclear or 
cytoplasmic (Silverman, 1984).
The E enzyme, in contrast to the ribonuclease F and the 
phosphodiesterase, is dsRNA-dependent (Sen, 1982) and in the 
presence of dsRNA can convert 97% of added ATP into (2-5)(A)n 
(where n ranges from 1 to 15) and pyrophosphates (Samanta et al.,
in
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FIG. 1. Outline of the 2-5 A system induced by IFN.
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1980) . The stoichiometry of the reaction has been formulated as:
(n+1)ATP — » (2'-5')pppA(pA)n + n pyrophosphate
2-5 A trimers, tetramers and pentamers are usually the pre­
dominant products (Kerr and Brown, 1978). However, the E enzyme 
can also catalyse the synthesis of 2 1-5' heteroligonucleotides 
with a structure of pppA21(p51 A)R2'p51N where N stands for rC, rG, 
rU, rT, dC, dG, or dA (Ferbus et al., 1981). Other substrates 
such as NAD and tRNA can be used by the E enzyme (Ferbus et al.,
1981) . The ability of the E enzyme to adenylate tRNA has suggested 
the hypothesis that by inactivating the tRNA the E enzyme inhibits 
protein synthesis (Justesen et al., 1985).
The E enzyme has been shown to be maximally active when the 
concentration of dsRNA is about one half that of the enzyme 
(Samanta et al., 1980). Negligible synthesis of 2-5 A was observed 
with added single stranded RNA, dsDNA or DNA-RNA hybrids (Minks 
et al., 1979). 2-5 A has been shown to be sensitive to snake
venom phosphodiesterase which cleaves 2'-5' bonds, and to bacterial 
alkaline phosphatase, which removes its terminal phosphates (Kerr 
and Brown, 1978). Micrococcal nuclease, nucleases Pj, T2, U2, 
pancreatic ribonuclease and spleen phosphodiesterase which cleave 
3 1-5' bonds are unable to degrade 2-5 A (Kerr and Brown, 1978).
E enzyme activity has been found in a wide array of animals 
(Stark et al., 1979). The E enzyme has been found in serum, 
spleen, lung (Krishnan and Baglioni, 1980), in a variety of cultured 
cells (Torrence, 1982) and in virions of VSV and MuLV grown in 
IFN-treated cells (Wallach and Revel, 1980). The level of E 
enzyme can be increased by any of the three types of IFN (Baglioni 
and Maroney, 1980; Hovanessian et al., 1980) but the level of
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the enzyme detected after IFN treatment varies among cell cultures. 
After IFN treatment the level of E enzyme could be increased in 
HeLa, L-cells, NIH-3T3 and lymphoblastoid cells (Minks et al.,
1979; Hovanessian and Kerr, 1979; Johnston et al., 1980;
Epstein et al., 1981), while MRC-5 cells were found to be 
resistant to any activation of the enzyme (Meurs et al., 1981).
Some cell cultures have high intrinsic levels of E enzyme 
(Verhaegen et al., 1980; Hovanessian et al., 1981) while others 
have very low levels (Meurs et al., 1981). Lymphoblastoid cells 
persistently infected with EBV, for example Daudi and Namalwa 
cells, have a high level of endogenous E enzyme (Johnston et al., 
1980; Tovey et al., 1983).
The kinetics of the induction of the enzyme by IFN vary 
between cells. L-cells showed an increase in the enzyme level
after a lag of 6 h while in BSC-1 cells the level increased after
about 2 h, and a maximum peak was usually reached in both cell
lines after 24 h of IFN treatment (Kimchi et al., 1979b).
The stimulation of the E enzyme was originally assayed in 
vitro by the ability of its product, 2-5 A, to inhibit protein 
synthesis in a cell-free system (Roberts et al., 1976; Hovanessian 
et al., 1977) but a more direct estimation of its activity was 
obtained by measuring the polymerization of ATP into 2-5 A 
oligomers. Labelled oligomers were then separated from ATP by 
DEAE-cellulose or after nuclease digestion by different methods 
such as thin-layer chromatography, high voltage paper electro­
phoresis or separation through alumina acid columns (Kerr et al., 
1977; Minks et al., 1979; Merlin et al., 1981). 2-5 A concentra­
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tions can also be determined by radiobinding and by radioimmuno­
assays (RIA)s (Knight et al.,_1980).
2-5 A dependent ribonuclease
2-5 A is responsible for the activation of an endoribo- 
nuclease called ribonuclease F (Schmidt et al., 1978) or L (Floyd- 
Smith et al., 1981). In order to activate this enzyme the 2-5 A 
has to be a trimer or longer and must have two 5' terminal 
phosphates and two free 3' OH groups (Williams et al., 1978). The 
activation of the partially purified nuclease (MW 185 000) by 2-5 
A is reversible; when 2-5 A is removed, the enzyme reverts to 
its latent form (Slattery et al., 1979). IFN can enhance the 
ribonuclease F activity but only very slightly (Silverman et al.,
1982). However, Jacobsen et al. (1983) have described a cell 
line (mouse JLS-V9R) in which, after IFN treatment, the level of 
the ribonuclease F increased ten to twenty-fold.
The activated 2-5 A endonuclease cleaves cellular and viral 
single-stranded mRNA equally but does not cleave single or dsDNA, 
dsRNA or homopolyribonucleotides (Nilsen et al., 1980). Ribosomal 
RNA can be cleaved in the naked form dr in situ in the ribosome 
(Baglioni et al., 1978). Experiments have shown that the enzyme 
cleaves predominantly atr the 3' side of"UA, UU and UG (Floyd- 
Smith et al., 1981; Wreschner et al., 1981).
The inhibition of protein synthesis andothe degradation of poly­
somes by the ribonuclease F has been determined in cell-free systems 
and in cultured cells using exogenous 2-5 A (Clemens and Williams, 
1978: Slattery et al., 1979). In cultured cells ribonuclease
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F activity is determined by introducing 2-5 A by calcium cop­
recipitation, lysolecithin or hypertonic media followed by- 
incorporation of labelled aminoacids (Williams and Kerr, 1978; 
Panet et a 1., 1981). The presence of ribonuclease F can also be 
detected by affinity labelling with radiolabel led 2-5 A (Wreschner 
et al., 1982).
In vitro, sensitivity to 2-5 A has been reported in L-cells, 
BHK-21, HeLa and RD-114 cells, while NIH-3T3 cells were resistant 
(Clemens and Williams, 1978; Williams and Kerr, 1978; Epstein 
et al., 1981; Panet et al., 1981; Sen et a 1., 1983; Silverman 
et al., 1983).
2-5 A can also inhibit RNA and DNA synthesis and inhibit 
cell growth but to a significantly lower level than protein 
synthesis inhibition (Hovanessian and Wood, 1980; Kimchi et al., 
1981).
2-5 A phosphodiesterase
2-5 A is resistant to most cellular nucleases because of its 
unusual 2'-5' phosphodiester bonds (Kerr and Brown, 1978). Never­
theless an enzyme called 2-5 A phosphodiesterase, that degrades 
2-5 Ap into AMP and ATP, has been partially purified from L-cells 
and has a MW of 40 000 (Schmidt et-al;,' 1979). This enzyme is 
also able to cleave 3S-5' bonds, to degrade the CCA terminus of 
tRNA and to inhibit tRNA aminoacylation (Schmidt et al., 1979).
By producing the latter actions the 2-5 A phosphodiesterase plays 
a role in the inhibition of protein synthesis in the IFN-dsRNA- 
independent pathway.
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The ability of IFN to activate the enzyme in cells varies.
A four to five-fold increase of 2-5 A phosphodiesterase activity 
after IFN treatment has been observed in L-cells while HeLa, RSA,
HEC and Daudi cells did not show any increase (Schmidt et al.,
1979; Silverman et al., 1982; Verhaegen-Lewalle and Content,
1982). The phosphodiesterase activity can be assayed by the 
degradation of 2-5 A and the degraded oligoadenylates separated 
by thin-layer chromatography or gel chromatography (Verhaegen- 
Lewalle and Content, 1982; Schmidt et al., 1979).
1.3.2.3. Other antiviral effects of IFN
Other ways in which IFN may reduce virus proliferation are 
by inhibiting virus budding from the cell membrane or by reducing 
virus particle infectivity. Inhibition of virus release by IFN 
has been demonstrated with MuLV, where IFN inhibited the formation 
of viral 4s RNA and caused a defect in viral assembly and release 
(Aboud and Hassan, 1983; Aboud et al., 1983). Biochemical 
changes such as reduction in glycoprotein and membrane protein 
in VSV particles grown in cells treated with IFN have been observed; 
these changes were responsible for the production of VSV with low 
infectivity (Maheswari et al., 1980).
1.4. PERSISTENT INFECTION AND IFN
In vitro a persistent, chronic infection is characterized 
by the continuous presence of viral genomes in the cells, which 
may or may not express antigens which are usually demonstrated
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by immunofluorescence (Rustigian, 1966; Gluzman et al., 1977; 
Nishiyama, 1977; Sato et al ♦, 1977; Weiss et al., 1980). In- 
vitro persistent infections are more readily established with 
RNA than DNA viruses and with negative-stranded RNA rather than 
positive-stranded RNA viruses, but examples of persistent infec­
tions can be found in all the major virus groups (Mahy, 1985).
Mechanisms by which persistence is induced and maintained 
can be studied more readily in vitro; such mechanisms usually 
involve the generation of virus mutants which interfere with 
wild-type replication and differ from parental virus in properties 
associated with structural proteins (Mahy, 1985). The virus 
mutant may be more or less resistant to inactivation by heat 
(ts mutants), pH, UV light, chemical agents or may have altered 
hemagglutinating activity (Rima and Martin, 1976; Friedman and 
Ramseur, 1979; Youngner and Preble, 1980). These changes reflect 
mutations in structural proteins with multiple functions in the 
virus replication cycle; the alteration may affect virus-specific 
RNA and protein synthesis as well as virion integrity and infectiv- 
ity (Rima and Martin, 1976; Friedman and Ramseur, 1979; Youngner 
and Preble, 1980).
The presence of defective interfering (DI) particles, which 
are virus particles lacking part of the genome, has been shown to 
be important in many-persistent -infections (Huang and Baltimore, 
1970; Holland et al., 1980). A persistent infection can also 
be established by integration of the virus genome into the host 
cell genome; this is the case with certain DNA viruses and retro­
viruses (Mahy, 1985). IFN has also been implicated in the 
production and maintenance of persistent infections by inhibiting
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viral replication (Sekellick and Marcus 1978. 1979, 1980; Friedman 
and Ramseur, 1979).
1.4.1. DNA viruses
1.4.1.1. SV40
A number of cell lines have been transformed by SV40 virus 
where part of the SV40 genome has been found to be integrated 
into the cell genome (Sambrook, 1972; Suarez et al., 1972;
Gluzman et al., 1977). The SV40-transformed cells are characterized 
by/the production of T antigens and by the absence or very low 
levels of virus particles (Sambrook, 1972; Suarez et al., 1972; 
Gluzman et al., 1977).
The antiviral effect of IFN on SV40 replication has been 
studied. Pretreatment of the cells with IFN inhibited the cyto- 
pathic effect of SV40 (Brennan and Stark, 1983). IFN treatment 
prior to infection inhibited the onset of early SV40 proteins 
by acting on RNA transcription, while IFN given after infection 
acted by inhibiting mRNA translation (Oxman and Levin, 1971;
Yamamoto et al., 1975; Metz et al., 1976; Yacobson et al.,
1977; Revel, 1979; Brennan and Stark, 1983).
In transformed 3T3-SV40 cells, IFN was unable to inhibit the 
production of SV40 T antigen (Oxman and Black', 1966; “ Oxman et al., 
1967) but could inhibit the transformation of 3T3 cells by 
exogenous SV40 (Todaro and Baron, 1965; Oxman and Black, 1966).
1.4.1.2. Hepatitis B virus (HBV)
Hepatoma cell cultures have been derived from primary liver
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carcinomas and some of these cell lines produce hepatitis B 
surface antigen (HBsAg) (Prozesky et al., 1973; Macnab et al., 
1976; Aden et al., 1979; Das et al., 1980; Oefinger et al.,
1981; Chang et al. > 1983). The presence of parts of HBV DNA 
integrated into the cell genome of HBsAg producer cell lines has 
been demonstrated by DNA hybridization in PLC/PRF/5 and Hep 3B 
cells (Marion et al., 1980; Twist et al., 1981).
IFN has been shown to have no effect on the production of 
HBsAg by PLC/PRF/5 cells and these cells did not produce endogenous 
IFN (Desmyter et al., 1981; Nakajima et al., 1982). However, IFN 
had an antiviral effect in these cells by inhibiting the replica­
tion of RNA viruses (Desmyter et al_., 1981) and by increasing the 
level of the E enzyme (Nakajima et a 1., 1982).
1.4.2. RNA viruses
1.4.2.1. Retroviruses
A number of workers have studied the effect of IFN on cells 
persistently infected with retroviruses. Type C retroviruses 
such as MuLV and RD-114 were most commonly used for these studies. 
In cells chronically infected with MuLV, IFN has been shown to 
produce an accumulation of MuLV particles at the cell surface 
and to prevent the release of newly formed virus particles 
(Biliau et al., 1976; Pitha et al., 1976; Aboud et al., 1982;
Sen, 1982). Inhibition of virus particle release by IFN was also 
found in cell lines persistently infected with type B or D 
retroviruses (Sen and Sarkar, 1980; Canivet et al., 1983).
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In NIH-3T3 cells, persistently infected with MuLV, IFN was 
able to activate the protein kinase and E enzyme while the 
ribonuclease F was absent (Epstein et al., 1981). Extracts 
from IFN-treated RD-114 cells persistently infected with RD-114 
virus showed no induction of the protein kinase (Tomita et al., 
1982b; Sen et al., 1983).
IFN has been shown to be able to inhibit penetration and 
the uncoating process of MuLV in NIH-3T3 cells (Aboud et al.,
1980; Salzberg et a 1., 1983a), and to prevent either the 
synthesis or integration of Kirsten murine sarcoma virus into 
the cell host genome and to stop cell transformation (Morris and 
Burke, 1979; Avery et al., 1980). This latter inhibition of 
proviral integration was not found with MuLV (Riggins and 
Pitha, 1982).
1.4.2.2. Togaviruses
Different factors have been implicated in the persistence 
of positive stranded RNA viruses such as Sindbis and rubella 
viruses (Maasab and Veronelli, 1966; Mifune et al., 1970; Inglot 
et al., 1973; Stanwick and Hallum, 1974; Norval, 1979; Weiss 
et al., 1980; Williams et al., 1981).
Infection with Sindbis virus is usually highly cytopathic 
but a persistent in f e c t io n  can be p roduced  by D I particles, by  
o th e r  v i r u s  m u ta n ts  o r  b y  IFN  ( I n g lo t  e t  a l . ,  1973; Weiss e t  a l . ,
1 980 ). I n g lo t  e t  a l .  (1973 ) showed th a t  a mouse c e l l  l i n e  c a r r y in g
S in d b is  v i r u s  p roduced  a s m a ll amount o f  IFN and th a t  th e  p resence
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of IFN was necessary for the survival of the cells. When anti- 
IFN antibodies were added to the cell medium virus multiplication 
increased and the cell culture was destroyed.
Persistent rubella virus infections have been reported in 
different cell lines and may be caused by a ts mutant, by the 
presence of DI particles or by direct transmission of virus from 
cell to cell or through cell division (Maasab and Veronelli,
1966; Mifune et al., 1970; Stanwick and Hallum, 1974; Norval, 
1979; Williams et al., 1981).
IFN was found unnecessary for the establishment or maintenance 
of chronic infections with rubella virus (Stanwick and Hallum,
1974; Sato et al., 1977; Williams et al., 1981), but was able 
to cure Vero cells of their persistent rubella infection (Stanwick
and Hallum, 1974).
1.4.2.3. Rhabdoviruses
Persistent infections with VSV and rabies viruses have been 
described (Kawai et al., 1975; Holland et al., 1976; Nishiyama, 
1977; Sekellick and Marcus, 1980; Andzhaparidze et al., 1981).
DI particles, ts mutants and IFN have been shown to help the 
establishment and maintenance of persistent infection of VSV and 
rabies viruses (Kawai et al., 1915; Uisfiiyama,-1977; Sekellick 
and Marcus, 1980; Andzhaparidze et al., 1981).
Sekellick and Marcus (1980) proposed a model for the 
regulatory effect of IFN in persistent infections with VSV in 
which high concentrations of IFN could cure the cells while 
lower concentrations permitted the virus to replicate and to
28
kill the cell.
IFN has also been shown to regulate the establishment of 
persistent infections of rabies virus in human neuroblastoma 
cells where the addition of anti-IFN in the cell media favoured 
the replication of the endogenous rabies virus (Honda et al.,
1984, 1985).
1.4.2.4. Paramyxoviridae
It has been possible to produce a persistent infection with 
a number of paramyxoviridae, e.g. NDV (Maeno et al., 1966), 
measles and subacute sclerosing panencephalitis (SSPE) viruses 
(Rustigian, 1966; Hallum et al., 1972; Stephenson et al., 1981; 
Carter and ter Meulen, 1983), Sendai virus (Ito et al., 1979,
1984) and mumps virus (Truant and Hallum, 1977; McCarthy et al., 
1981; Ito et al., 1985).
Paramyxoviridae are negative stranded RNA viruses and 
persistence in cells is obtained using ts strains, by the presence 
of DI particles or by alteration of the viral-cellular system 
relationship (Rustigian, 1966; Truant and Hallum, 1977; Ito 
et al., 1979, 1984; Wechsler et al., 1979).
Production of IFN was noted in cells persistently infected 
with paramyxoviridae such as NDV, Sendai-, measles and mumps 
viruses but the presence of IFN was not always considered critical 
for the establishment or the maintenance of the persistent infec­
tion (Hallum et al., 1972; Rima and Martin, 1976; Ito et al., 
1976, 1985). Cell lines persistently infected with measles and 
Sendai viruses which do not produce IFN have been reported (Maeno
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et al., 1966; Wild and Dugre, 1978); however, Ito et al. (1985) 
have shown the importance of IFN in the persistent infection of 
mumps virus in L-cells.
1.5. AIMS
After its discovery in 1957 by Isaacs and Lindenman, research 
on IFN as an antiviral drug multiplied, but later, as it was 
difficult to produce workable quantities, research was hampered.
A few virologists continued, nevertheless, to work with IFN, and 
Strander and Cantell in 1966 brought IFN back to prominence by 
obtaining a large amount as a byproduct of blood banking. In 
1979 Cantell predicted that by the year 2000 different kinds of 
IFNs would be used routinely for the treatment of a number of 
diseases and encouraged the production of lymphoblastoid IFN and 
<*-IFN in every country where there was a blood banking system.
In 1980, in South Africa, Schoub et al. announced the feasibility 
of mass production of IFN and the importance of further research 
with IFN if it was to be used as an antiviral drug.
With the advent of recombinant DNA technology and the 
production of recIFNs the drawback of the low amounts of IFN fell 
away and in-vitro and in-vivo studies on IFN and its effects 
multiplied (Dunnick et al., 1981).
One of the fields still to be investigated is the relation­
ship between IFN and a persistent viral infection. Persistent 
infections with HBV lead to chronic liver disease or hepatoma 
while a persistent infection with measles virus may lead to SSPE. 
In South Africa chronic hepatitis and measles affect a large
percentage of the population and the knowledge of the role of 
IFN in chronic virus infection could bring about a better under­
standing of the mechanisms of persistence in viral diseases.
The aim of this thesis was to examine the role of IFN in viral 
persistence at the cellular level. For this purpose two types 
of persistent infections were chosen. The first type was cell 
lines which contained integrated HBV or SV40 DNA. In the second 
type, persistent infection with two RNA viruses, SSPE and Sendai 
virus, were chosen. These virus systems were examined to 
determine:
1) what effect IFN has in these persistent viral infections 
in vitro in terms of its antiviral and antiproliferative 
effects and to compare the results obtained with control 
cells
2) which of the two major enzyme systems, E enzyme or protein 
kinase, was induced, and whether this correlated with the 
antiviral results
3) whether there were any differences, in terms of the 
sensitivity to IFN, between the RNA and DNA viruses in 
persistent infections.
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CHAPTER 2
MATERIALS AND METHODS
2.1. REAGENTS AND MATERIALS
Analytical reagents were from Merck, Darmstadt, West Germany 
or from BDH Chemicals, England, and were of Analar or the highest 
available quality. Fine chemicals were from Sigma Chemical Co.,
MO, USA or from Boehringer, Mannheim, West Germany.
Radiochemicals were from Amersham International, Amersham, 
England, and fluorescein isothiocyanate (FITC) conjugated anti­
body products were from Cappel Laboratories, PA, USA.
RPMI 1640, Eagle's minimum essential medium (EMEM) plus 
non-essential amino acids, and Dulbecco minimum essential medium 
(DMEM) were from Gibco Lab., Grand Islands, NY, USA. Foetal calf 
serum (FCS), filtered and UV-irradiated, was from the State 
Vaccine Institute, Pinelands, South Africa.
The eIF-2 preparations were kindly provided by Prof. K.L. 
Manchester, University of the Witwatersrand, Johannesburg, South 
Africa, (Sample A), and by Dr. J. Siekerka, Roche Institute, NJ,
USA, (Sample B).
Human IFN reference standard G023-901-527 and mouse IFN (MuIFN) 
reference standard G002-904-511 were from the National Institute 
for Allergy and Infectious Diseases, Bethesda, MD, USA. Recombinant 
leucocyte A IFN (R022-8181; IFL-rRA) was a gift from Roche, Basel, 
Switzerland.
Tissue culture flasks were from Costar, MA, USA, and Corning, 
NY, USA. Petri dishes (60 x 15 mm) and 6-multiwell plates were
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from Costar, MA, USA, while 24 and 96-multiwell plates were 
from Linbro, Flow Lab., Scotland.
Centrifugation was performed in the following machines : 
Coolspin MSE, MSE Scientific Instr., Sussex, England, Beckman 
L88-55 Ultracentrifuge, Beckman Instr. Inc., CA, USA and Eppen- 
dorf Microfuge 5412, Eppendorf Geratebau, Hamburg, West Germany.
Photographs were taken with an Olympus OM-1 with a 50 mm 
lens; Ilford 125 ASA film was used and developed as directed 
by Ilford.
2.2. STOCK CULTURES
2.2.1. Cell lines
In Table 2 are shown the origin and source of cell lines 
used in this thesis.
2.2.1.1. Hepatoma cell lines
Hepatoma cell lines used in this study were derived from 
human hepatocellular carcinomas with the exception of Hep G2 
which was derived from an hepatoblastoma. PLC/PRF/5 and Hep 3B 
cells are the only cell lines that produce HBsAg. Details of the 
hepatoma cells used in this study are shown in Table 3.
2.2.1.2. CV-1 cell lines
The effects of IFN on CV-1 cell lines with integrated SV40 
DNA, (C2, C6, C11), were compared with a control, uninfected, CV-1
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TABLE 2. The origin and source of cell lines used in this thesis
CELL LINE ORIGIN VIRUS
PRESENT
SOURCE REFERENCE
L-cells Mouse None 2
NIH-3T3 Mouse MuLV 2 Jainchill et al., 1969
PLC/PRF/5 Human HBV * 3 Alexander et al., 1976
Hep 3B Human HBV * 4 Aden et al., 1979
Mahlavu Human None . 5 Prozesky et al., 1973
Hep G2 Human None 4 Aden et al., 1979
HA22T/VGH ** Human None 6 Chang et al., 1983
CV-1 Primate None 1
C2 Primate SV40 * 7 Gluzman et al., 1977
C6 Primate SV40 * 7 Gluzman et al., 1977
Cll Primate SV40* 7 Gluzman et al., 1977
Vero Primate None 1
SSPE-Vero Primate SSPE 8 Stephenson et al., 1981
Sendai-Vero Primate Sendai 1
Namalwa Human EBV 9 Klein et al., 1972
* Integrated viral DNA 
** Referred to in the text as HA22T
1. National Institute for Virology (NIV), Johannesburg* South Africa.
2. Dr. A. Panet, Hebrew University, Jerusalem, Israel.
3. Dr. J.J. Alexander, Medical University of Southern Africa,
South Africa.
4. Dr. D.P. Aden, Wistar Institute, Philadelphia, PA, USA.
5. Prof. O.W. Prozesky, University of Pretoria, Pretoria, South
Africa.
6. Prof. C. Chang, National Yang Ming Medical College, Taipei, Taiwan.
7. Prof. E. Winocour, Weizman Institute, Rehovot, Israel.
8. Prof. V. ter Meulen, University of Wurzburg, Wurzburg, West
Germany.
9. Prof. M. Revel, Weizman Institute, Rehovot, Israel.
TABLE 3. Hepatoma cell lines used in this thesis
CELL LINE HBV
PRESENT
HBsAg
PRODUCTION
PLC/PRF/5 yes yes
Hep 3B yes yes
Mahlavu no no
Hep G2 ' no no
HA22T no no
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cell line. Details of the CV-1 cells used in this thesis are 
shown in Table 4.
2.2.1.3. SSPE-Vero cell lines
A SSPE-Vero cell line derived from Vero cells co-cultivated 
with SSPE virus-infected brain cells was used in this thesis.
Using the supernatant of this cell line, which contained a virus 
concentration of 6.2x 10'TCIDg0/ml, secondary cell lines persistently 
infected with SSPE virus were established. Vero cells at 80% 
confluency were incubated with SSPE-Vero cell supernatant and 
when confluent were trypsinized and subcultured. After a few 
passages, usually at the second one, syncitia were seen and by 
the following passage the majority of the cells were detached.
The few surviving cells were incubated with several changes of 
EMEM containing 5% FCS. Distinct colonies appeared after two to 
three weeks; the colonies were then trypsinized and subcultured.
The monolayer, which was thus established, was trypsinized and 
subcultured when it reached confluency.
2.2.1.4. Sendai-Vero cell lines
A Sendai-Vero cell line was established by inoculating Vero 
cells with approximately 30 pfu/cell of Sendai virus and incubated 
for 1 h at 37°C. The viral fluid was then removed and replaced 
with EMEM containing 2% FCS. The cells were passaged when confluent 
and after few passages, the majority of the cells detached. The 
few surviving cells were incubated with several changes of EMEM
TABLE 4. CV-1 cells used in this thesis
CELL LINE SV40 T Antigen
PRESENT PRODUCTION
CV-1 no no
C2 yes yes
C6 yes yes
Cll yes yes
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containing 5% FCS. Distinct colonies were seen after fourteen 
days and these reached confluency fifteen days later. The cells 
were then trypsinized and subcultured.
2.2.2. Virus stocks and antisera
2.2.2.1. Viruses
The Edmonston strain of measles virus from the virus bank
of NIV was passaged in Vero cells. When the Vero cells reached
_2
confluency of 80%, a 10 dilution of measles virus was added 
and the culture left for 1 h at 37°C on a rocker platform (Bellco 
Glass Inc., Vinelands, NJ., USA). The inoculum was then aspirated 
and replaced with EMEM + 2% FCS. After five days, when there 
was significant formation of syncitia, the virus was harvested by 
freeze-thawing. Measles virus was stored at -70°C and titrated 
by plaque assay and end-point dilution (Table 5).
SSPE virus produced by SSPE-Vero cells was titrated by the 
end point dilution test (Table 5). The presence of syncitia 
produced by the virus in SSPE-Vero cells could be seen by light 
microscopy (Figs. 2, 3).
Sindbis virus was-a gift from Dr. J. Desmyter, Rega Institute, 
Leuven, Belgium. A stock preparation was produced using Vero cells. 
When Vero cells reached confluency of 70%, Sindbis virus at a 
dilution of 10~3 in EMEM was added and adsorbed for 1 h at 37°C.
The inoculum was then aspirated and the monolayer incubated at 
37°C; when the Vero cells showed a cytopathic effect, the virus 
was harvested by freeze-thawing. The virus was stored at -70°C 
and titrated by plaque assay and end point dilution (Table 5).
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TABLE 5. Titres of viruses used
VIRUS TYPE OF ASSAY RANGE OF TITRES
Measles
Plaque assay 3xl05 - 6.8xl06 pfu/ml
End Point dilution 5xl06 - 5xl07 TCID50/ml
SSPE End Point dilution 6.2xl01 TCID50/ml
Sindbis
Plaque assay 1.8xl06 -2.6xl06 pfu/ml
End Point dilution 6.9xl05 -1.4xl06 TCID50/ml
Sendai
Haemagglutination 960 - 1280 HAU
Plaque assay 4.8xl07 -1.5xl09 pfu/ml
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FIG. 2. Light microscopy of SSPE-Vero cells showing syncitia. 
Cells were examined in a Nikon microscope at 200x 
magnification.
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FIG. 3. Light microscopy of SSPE-Vero cells showing syncitia. 
Cells were examined in a Nikon microscope at 400x 
magnification.
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Sendai virus E82 was a gift from Dr. K. Cantell, Central 
Public Health Lab., Helsinki, Finland, and was passaged in chicken 
eggs. Embryonated eggs were incubated for 11 days at 37°C, then 
inoculated with a 10"4 dilution of Sendai stock virus in phosphate 
buffered saline (PBS) pH7.4, into the allantoic cavity. The 
eggs were incubated for three days at 37°C and then chilled 
overnight (o.n.) at 4°C; the allantoic fluid was harvested and 
titrated using the plaque assay and the haemagglutination (HA) 
test (Table 4). The stock virus was stored at -70°C until used.
2.2.2.2. Antisera
Bovine anti-measles serum was obtained from Wellcome Diagnos­
tics, Dartford, England; guinea pig anti-measles sera were 
obtained from the National Institute for Allergy and Infectious 
Diseases, Bethesda, MD, USA, and from the Behring Institute, 
Marburg, West Germany. Human anti-measles sera, with a titre 
^1:128 in the complement fixation test, were obtained from the 
NIV serum bank and from Prof. J. Moodie, University of Cape Town, 
South Africa.
Sindbis antiserum was prepared as immune ascitic fluid in 
mice (Lyons et al., 1982). A mouse brain suspension was prepared 
from suckling mice that had been injected intracerebrally with
_5
a 10 dilution of freeze-dried infected mouse brain. When the 
suckling mice became ill the brains were harvested (in lots of 
5) and a 10% suspension of infected suckling mouse brain in 
saline was prepared. This suspension was mixed with an equal 
quantity of Freund's complete adjuvant (Gibco, NY, USA) and
inoculated intraperitonally (i.p.) into weanling mice (0.2 ml/-
mouse) at four weekly intervals...On the... fifth..week ..the mice
were injected i.p. with 0.2 ml of sarcoma 180/T6 ascitic fluid 
taken directly from a donor mouse with ascites and 10-12 days 
post-inoculation the ascitic fluid was collected by paracentesis. 
This was defibrinated with glass beads, centrifuged to remove 
the fibrin, inactivated at 56°C for 30 min and then recentrifuged. 
The antiserum was stored at -70°C until used.
Sendai antiserum was made by injecting adult mice intra­
muscularly (i.m.) with a 10"1 dilution of a stock preparation 
of Sendai virus (0.2 ml/mouse), four times over a two month 
period; the last injection was given i.p. A week later the mice 
were injected i.p. with 0.2 ml of sarcoma 180/TG ascitic fluid 
taken from a donor mouse with ascites. Thirteen to fourteen 
days later the ascitic fluid was collected and the fibrin removed 
by centrifugation. The antiserum was inactivated at 56°C and 
stored at -70°C.
2.3. CELL GROWTH AND SUBCULTURE
In this study all cells were grown as monolayer.cultures
except the Namalwa cells which were grown in suspension. Mono-
2layer cells were grown in 75 cm flasks in medium containing 
FCS (Table 6) and were subcultured when they reached confluency. 
The expended medium was decanted, the monolayers washed with 
serum-free medium and trypsin (0.25%) and EDTA (0.1%) (at a 1:1 
ratio) were added and left until the cells started to detach 
from the flask. The cells were then resuspended in the growth 
medium indicated in Table 6. The frequency of subculturing is
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TABLE 6 . Culture media used for each cell line, and the number 
of subcultures per week for each cell line
CELL LINE MEDIUM NO. SUBCULTURES 
PER WEEK
L-cells EMEM + 5% FCS 2
NIH-3T3 EMEM + 5% FCS 2
PLC/PRF/5 EMEM + 10% FCS 1
Mahlavu EMEM + 10% FCS 1
Hep 3B EMEM + 10% FCS 1
Hep G2 EMEM + 10% FCS 1
HA22T EMEM + 10% FCS 1
CV-1 RPMI 1640 + 10% FCS 1
C2 DMEM + 10% FCS 1
C6 DMEM + 10% FCS 1
Cll DMEM + 10% FCS 1
Vero EMEM + 5% FCS 2
SSPE-Vero EMEM + 5% FCS 2
Sendai-Vero EMEM + 5% FCS 1
Namalwa RPMI 1640 + 20% FCS 1
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also shown in Table 6. Viable cell counts were determined by 
adding 0.5% (w/v) trypan.blue in PBS to the cell suspensions 
at a ratio of 3:1 and the cells were then counted using a 
haemocytometer.
2.3.1. Storage of cell lines
Confluent cells were trypsinized as above and resuspended 
in medium containing 20-40% FCS and 10% glycerol at a concentra­
tion of 2 x 10® viable cells/ml. Cells were dispensed in 1.5 ml 
aliquots in Nunc ampoules (Interned, Denmark), left for 1 h at 
4°C, followed by 1 h at -20°C in a polystyrene box and then 
stored at -70°C or in liquid nitrogen. Frozen cultures were 
thawed rapidly at 37°C and diluted slowly in 5 ml medium containing
10 or 20% FCS. The resulting cell suspensions were placed in 
2
25 cm flasks and subcultured after reaching confluency.
2.4. VIRUS TITRATION
2.4.1. End-point dilution
Cells, seeded in 96-multiwell plates using 0.1 ml of the 
appropriate cell concentration per well, were incubated with 0.1 ml 
of virus diluted serially two-fold or ten-fold; the plates were 
then incubated at 37°C in a 5% CO2  incubator. The wells were 
observed daily for the presence of cytopathic effect, and after 
approximately 10 days the KID^/ml calculated according to the 
method of Reed and Muench (1938).
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2.4.2. Plaque assay
Vero cells, seeded in Petri dishes, were inoculated with 
serial ten-fold dilutions of virus when they were 90% confluent. 
After 1 h adsorption at 37°C the virus was aspirated. The mono- 
layers were covered with 8 ml of 1% Sea-agarose (FMC Corp. Rockland, 
ME, USA) in EBME buffer (0.8% Hepes, 0.11% NaHCOg containing 
5 pg/ml of trypsin). The trypsin was omitted in the case of 
measles virus. The overlay was allowed to solidify and the 
plates incubated in an inverted position for 4 days. Neutral 
red (0.1% w/v in PBS) was added and left for 4 h at room temperature 
(RT) in the dark. The excess neutral red was poured off and the 
plates kept in the dark at RT. The next day the plaques were 
counted and the plaque forming units (pfu)/ml calculated.
2.4.3. Haemagglutination test
The HA test was done in 96-multiwell plates. To each well 
was added 100 pi of the appropriate dilution in PBS plus 100 pi 
of 0.5% fowl red blood cells in saline; the plate was left at 
RT for 45 min. The plate was then read and the highest dilution 
of the virus with complete haemagglutination was considered 
the end point of the titration (Salk, 1944) and this titre was 
given in HA units (HAU).
2.4.4. Immunofluorescence
Ten microliter of cells (1 x 106 cells/ml) suspended in
saline plus 5% FCS were fixed onto slides with cold acetone; 
the slides were then air-dried and stored at -70°C if not used 
at once. The fixed cells were incubated with the specified 
antibody for 15-30 min at 37°C in a humidified box. The slides 
were washed for 10 min in warm PBS and then incubated with FITC 
conjugated antibody in 0.05% Evans blue at 37°C for 15-30 min.
The slides were then washed for 10 min in warm PBS, air-dried 
and covered with mounting fluid (10% glycerol in PBS) and a 
cover-slip. The immunofluorescence was read using the immuno- 
fluorescent microscope with a Fluoro lOx or 20x lens.
2.5. INTERFERON PREPARATION
2.5.1. Lymphoblastoid IFN
Lymphoblastoid IFN was prepared following the method of 
Lyons et al. (1982) using Namalwa cells which have been shown 
to produce high levels of IFN with Sendai virus and sodium butyrate 
(Strander et al., 1975; Baker et al., 1980; Johnston, 1980).
Namalwa cells were kept in suspension culture in RPMI 1640 
plus 10% FCS and maintained at a concentration of 1 x 10® cells/ml 
by splitting two or three times per week. Duran Scott IS 
bottles, rolled on a cell production roller apparatus (Bellco 
Glass, Inc., Vinelands, NJ) at approximately 0.25 rev/min-, were 
used to maintain the Namalwa cells in suspension. To produce 
IFN, the cells were adjusted to a concentration of 0.5 x 10® 
viable cells/ml in RPMI 1640 supplemented with 2% FCS and 100 ml 
aliquots were placed into tissue culture flasks (75 cm ). Sodium 
butyrate was added to a final concentration of 1 mM. After 
incubation at 35°C for 48 h, the suspension was centrifuged and
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each cell pellet resuspended in 30 ml of RPMI 1640 plus 2% FCS. 
Sendai virus was used for induction at a concentration of 100 
HAU/106 cells. The cell suspension was incubated for 18-25 h 
at 37°C after which the supernatants were harvested and clarified 
by centrifugation. The pH of the supernatant fluid was adjusted 
to 2.0 with concentrated HC1, held at 4°C for 72 h to inactivate 
the virus, and then returned to pH 7 with 1 N NaOH. The IFN 
produced was assayed, using the RIA, for sensitivity to raised 
temperature (56°C) for 30 min, trypsin (100 jjg/ml) for 30 min 
at 37°C, ultracentrifugation (100 000 g for 2 h) and tp pH 2.
The IFN preparation was found to be sensitive to 56°C and to 
trypsin, while IFN activity was found after a high speed centri­
fugation and after treatment at pH 2. The IFN was titrated 
against the human IFN reference standard and was found to have a 
titer of 16 000 IU/ml. The IFN preparation was kept at -70°C, 
and this preparation was used throughout this thesis if not 
otherwise indicated.
2.5.2. MuIFN
MuIFN was produced in L-cells induced with Sendai virus 
(Lyons et al., 1982). Confluent monolayer cells were washed twice 
with warm EMEM and then 200 HAU of Sendai virus per-10^/celIs 
were added. After incubation at 35°C for 1 h the inoculum was 
removed and replaced with fresh EMEM supplemented with 2% FCS. The 
cells were incubated for 18-24 h at 35°C after which the supernatant 
was harvested and clarified by centrifugation. The pH of the 
supernatant was adjusted to pH 2.0 with concentrated HC1 and 
h e ld  a t  4°C f o r  72 h t o  i n a c t i v a t e  th e  v i r u s ,  th e n  r e tu r n e d  to
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pH 7 with 1 N NaOH. The IFN was titrated against the mouse 
reference standard and had an activity of 3 x 10^ IU/ml. It 
was stored at -70°C in 100 pi aliquots.
2.5.3. Mock IFNs
Mock IFNs were prepared following the same procedure for 
lymphoblastoid or MuIFN but no virus inducer was added to the 
cells.
2.6. ANTIVIRAL ASSAYS
2.6.1. Radioimmunoassay
The indirect RIA fallowing the method of Lyons et al. (1982 
was used. Cells were seeded in 96-multiwell plates and incubatei 
at 37°C in 5% CO2  until the cells were confluent. The spent 
medium was removed by aspiration and replaced with 100 pi of 
diluted IFN. EMEM with 5% FCS was used as a diluent and a nega­
tive control. The plates were incubated at 37°C in 5% CO2  for 
18-24 h, the IFN removed and the cells washed twice with warm 
EMEM. To each well was added 100 pi of Sindbis virus at the 
appropriate dilution. The appropriate dilution of Sindbis virus 
was previously determined by titrating the virus in the same 
RIA system and by choosing the dilution which gave a value of 
approximately 1 000-2 000 counts/min (cpm). After adsorption of 
the virus for 1 h at 37°C the unattached virus was removed by 
aspiration, 100 pi of fresh EMEM containing 2% FCS added to each 
well and the plate incubated o.nu: at 37°C in 5% CO2 . The medium
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was then removed and the plates washed three times with warm
wash-buffer fPBS, 0.1% bovine serum albumin (BSA), 0.02% sodium
azide and 0.05% Tween 20]. After air-drying for 10 min the
monolayer cells were fixed with chilled methanol and the plate
placed at -20°C for 10 min. The methanol was then removed and
the plate air-dried. After drying, the wells were washed three
times with wash buffer? and approximately 200 jjI of the same
buffer was added to each well. The plates were incubated at
37°C for 1 h, the wash buffer was then removed and replaced
with 50 |7l of anti-Sindbis antiserum which was used at antibody
excess. After a further hour at 37°C the antiserum was removed
and the plates washed three times with wash buffer. To each
1well was added 100 pi of I-protein A previously adjusted to 
30 000 cpm/100 |jl, using wash buffer as diluent. The plates 
were again incubated for 1 h after which the wells were washed 
four times with wash buffer. The cells were solubilized with 
0.1 N NaOH +0.1% sodium dodecyl sulphate (SDS), 100 Jjl/wel1, 
for 1 h at 37°C. Fifty |il of solubilized material was then 
counted in a y-counter. Each sample was tested in duplicate 
in each assay and the average count for two wells used in the 
calculations. The results are given in IFN IU/ml which is the 
equivalent of the concentration of IFN needed to produce a 50% 
Sindbis virus reduction in comparison-to the-virus -control well, 
as measured by cpm/well.
2.6.2. Immunofluorescence
Cells were grown in multiwell Bellco chambers (Bellco Glass
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Inc. Vinelands, NJ, USA) and when they were 80% confluent the 
EMEM was aspirated and replaced with dilutions of IFN. After 
24 h at 37°C in 5% (X^ the IFN was removed and replaced with the 
appropriate dilution of Sindbis virus and the chambers left for 
1 h at 37°C in 5% CO2 . The appropriate dilution of Sindbis 
virus was previously chosen by titrating the virus in the same 
system, but without IFN, and taking the lowest dilution of the 
virus that produced immunofluorescence. The unattached virus 
was aspirated and EMEM + 2% FCS was added. After two to three 
days incubation at 37°C in 5% CO^ the cells were examined for 
immunofluorescence, and the lowest dilution of IFN that inhibited 
virus replication determined.
2.6.3. Radioimmunoprecipitation (RIPA)
Cells were grown at 37°C and when they reached a confluency
of 80%, IFN was added for 24 h. The IFN was then removed and
virus added and left for 1 h at 37°C. The viral fluid was then
discarded and replaced with EMEM + 2% FCS and the cells incubated
at 37PC for 24 h or as indicated. The medium was replaced with
methionine-free medium for 1 h and then for 2-24 h 'with methionine-
35free medium containing 20 yCi/ml of S-methionine. The cells 
were washed once with chilled PBS, scraped off i n 1 ml of PBS 
and pelleted by centrifugation. The cells were lysed in 0.5% 
w/v Nonidet-P 40 (NP40) in NETBSA-NP40 (0.5% w/v NP40, 150 mM 
NaCl, 5 mM EDTA, 50 mM Tris-HCl, 1 rtig/ml BSA, pH 7.4) and the 
nuclei removed by centrifugation at 3 000 rpm for 10 min at 4°C.
The viral intracellular proteins in the supernatant were immuno-
precipitated with the specific antiserum using the method of 
Struthers and Swanepoel (1982). Cell extracts were incubated 
for 4-6 h at 4°C with the antiserum and then for 4 h or o.n. 
with 8 mg/ml of protein A-sepharose beads CL-4B (Pharmacia, 
Sweden) in NETBSA-NP40 at 4°C. The beads were then washed six 
times with NETBSA-NP40 buffer, resuspended in 100 pi dissociation 
buffer (10% SDS, 10% 2-mercaptoethanol, 15% glycerol, 0.01% 
bromophenol blue in 1 M Tris pH 6.8) (Laemmli, 1970) and boiled 
for 5-10 min. Virus specific polypeptides were then analysed 
by linear 12% SDS polyacrylamide slab gel electrophoresis (PAGE), 
run in parallel with MW markers and visualized by fluorography 
(see 2.11).
2.7. ANTIPROLIFERATIVE ASSAYS
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2.7.1. H-thymidine incorporation
Cells were plated in 24-multiwell tissue culture plates in 
EMEM supplemented with 10% FCS. Different dilutions of IFN or 
mock IFN were added at the time of plating and the cells incubated 
for 48 h at 37°C in a COg incubator. Mitotic activity was then
O
measured by pulsing with H-thymidine at 2 pCi/ml in EMEM with ■ 
10% FCS for 1 h. The cells were then washed with cold PBS, 5% 
trichloroacetic acid (TCA) was added to each well and the plate 
held for 30 min at 4°C. After a further two washings with 5%
TCA the cells were solubilized with 0.1 N NaOH containing 0.1%
SDS and the plate incubated at 37°C for 1 h. The samples were 
neutralized with 1 M HC1 and then counted in a scintillation 
counter. The percentage inhibition of TCA precipitable counts,
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determined by comparing untreated cells and cells treated with 
various IFN dilutions, was recorded. Each cell line was tested 
three times and the mean of three counts was determined.
2.7.2. Cell counting
Cells were plated in Petri dishes (60 x 15 mm) in EMEM 
containing 5 or 10% FCS as indicated (Table 6). When the cells 
reached 80% confluency the medium was removed and 2.5 ml of IFN, 
at varying dilutions, was added. The Petri dishes were left at 
37°C in 5% C02 for 48 h, then the cells were trypsinized and 
viable cells determined by trypan blue exclusion. Each IFN 
dilution was tested in duplicate and the assays repeated at 
least three times for each cell line.
2.8. E ENZYME ASSAY
The level of E enzyme in the cells was measured as described
by Schattner et al. (1981). Cells were grown to confluency in 
2
150 cm flasks in EMEM containing 5 or 10% FCS with or without 
lymphoblastoid IFN (200 IU/ml) or mock IFN. After trypsinization 
the cells were washed with cold PBS and resuspensed in lysis 
buffer B Q>0 mM Hepes buffer pH-7.5, 5 mM MgCL,, 120 mM KC1, 7mM 
dithiothreitol (DTT), 10% (v/v) glycerol, and containing 0.5% 
NP4o3- Lysis was carried out at 4°C and the extract centrifuged 
for 6 min at 8 000 x g. The supernatant was stored at -70°C in 
aliquots if not used immediately. Cell extracts (10 |jl) were 
mixed with agarose poly (1) (C) beads and incubated for 15 min
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at 30°C. A reaction mixture (10 jjI) of 10 mM Hepes pH 7.5, 5 mM 
MgCl2, 7 mM DTT, 10% (v/v) glycerol, 2.5 mM o^P-ATP (100-300 
Ci/mmol), 3 mg/ml creatine kinase, 10 mM creatine phosphate and 
40 |jg/ml poly (I) poly (C) was added to the preparation. After 
21 h incubation at 30°C, 20 pi of calf alkaline phosphatase 
(150 U/ml) in 1 M Tris base was added to the preparation and incuba­
tion was continued for 2 h at 37°C. Each extract mixture was 
then applied to an acid alumina column, which bound the free 
phosphate, and the cores of 2-5 A eluted with HCl-glycine- 
pH 2.3. The results were given in pmoles of 2-5 A/h/pg protein.
The amount of protein in each extract was calculated using the 
BIO-RAD assay kit which is based on the shift in the maximum 
absorbance of Coomassie blue 6250 from 465 to 595 when protein 
binding occurs (Bradford, 1976). Five ml of dye reagent was 
added to 0.1 ml of diluted sample and after 5-60 min the absorbance 
was read at 595 nm in a Pye Unicam spectrometer. A standard 
curve of absorbance versus concentration of protein was drawn 
using BSA (0-1 mg/1) and the unknown protein concentration read 
off the curve.
2.9. RIBONUCLEASE F ASSAY
Cells were plated in 24-multiwell plates in EMEM containing 
5 or 10% FCS and incubated at 37°C in a humidified 5% CO2  atmos­
phere. When the cell growth was approximately 75 to 80% confluency, 
the medium was aspirated, the cells washed with EMEM and then
incubated for 1 h at 37°C with EMEM. Serial logarithmic dilutions 
-6 -9of 2-5 A, from 10 to 10 M, were made in transfection buffer
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(0.02 M Hepes, pH 7.08, 0.13 M NaCl, 5 mM KC1, 0.7 mM Na2HP042H20, 
6 mM glucose). The 2-5 A was introduced into the -cells by calcium 
coprecipitation (Hovanessian and Wood, 1980); CaCl2 (2.5 M) 
was added to the cells at a final concentration of 114 mM. After 
10 min at RT, when a fine precipitate had formed, the 2-5 A 
dilutions were added to the cells. The plates were left at RT 
for 45 min and then transferred to 37°C for 90 min. The solution 
was aspirated, replaced with EMEM containing 10% FCS and the plate 
incubated for 105 min at 37°C. The medium was then changed to
3
EMEM without leucine to which 1 [jCi/ml of H-leucine was added. 
After a further hour at 37°C the cells were washed with PBS,
1 ml of 5% TCA was then added to each well and the plate held 
for 30 min at 4°C. The cells were then washed twice with 5%
TCA, digested with 1 ml of 0.1 M Na0H-0.1% SDS for 1 h at 37°C 
and then neutralized with 0.1 ml of 1 M HC1. The radioactivity 
of the samples was counted after dilution into liquid scintillant. 
The level of ribonuclease F activity was determined by the
3
reduction in H-leucine uptake.
2.9.1. 2-5 A uptake
The uptake of 2-5 A was tested by introducing into 80% 
confluent monolayers 0.1 mM of 2-5 A containing 2.5 |iCi of 2-5 A 
tetramer 5'-triphosphate, 3'-(^2P)pCp (2-5 A-^2P) with transfec­
tion buffer containing 114 mM CaC^- After 45 min at RT the 
medium was removed and the cells washed twice with cold PBS.
The cells were lysed with lysis buffer B containing 0.5% NP40, 
and the extracts counted in a scintillation counter. The ratio
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of incorporation of labelled 2-5 A into the cells was calculated.
32A comparison of 2-5 A- P incorporation was made between cells 
treated with transfection buffer with and without CaCl2. The 
permeability of the cells was also checked by trypan blue 
exclusion. Trypan blue was diluted in transfection buffer with 
or without CaCl2 and incubated with the cells for 45 min at RT.
2.10. PROTEIN KINASE
The phosphorylation of PI (MW 69 000) and oC-eIF-2 were 
tested as described by Samuel (1981). A confluent monolayer 
was incubated at 37°C in the absence or presence of IFN (200 
IU/ml) or mock IFN for 24 h before harvesting. The cells were 
then washed three times with chilled isotonic buffer (35 mM 
Tris-HCl pH 6.8, 146 mM NaCl, 1 mM glucose) and disrupted by 
the addition of lysis buffer B. After 10 min agitation, the 
cells were scraped off with a rubber policeman and centrifuged at 
800 rpm for 10 min at 4°C. The cell extract was then centrifuged 
at 10 000 x g. The resulting supernatant was then stored at -70°C 
in aliquots. Cell extracts (10 pi) were incubated 30 min at 
30°C with 20 mM Hepes (pH 7.5), 100 mM KC1, 4 mM MgCl2, 1.5 
mM DTT and 100 [iM ATP containing 5-10 pCi of 32P-ATP (30 Ci/mmol) 
and as indicated with 1 pg/ml of dsRNA and/or eIF-2 (2 pg).
The reaction was stopped by the addition of 200 pi dissociation 
buffer (Laemmli, 1970) and the samples boiled for 5 min. The 
P labelled products were analyzed by SDS-PAGE followed by auto­
radiography.
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2.11. SDS-PAGE
Polypeptides were analyzed by PAGE using the discontinuous 
system of Laemmli (1970). The resolving gel (14 x 17 x 0.3 cm) 
contained 0.37 M Tris-HCl pH 8.8, 0.1% SDS and 12% bis-acrylamide 
(ratio of acrylamide : bisacrylamide 30: 0.8). A 2 cm stacking 
gel containing 0.126 M Tris-HCl pH 6.8, 0.1% SDS and 4% bis­
acrylamide was cast on top of the gel and 10 or 20 wells made in 
this gel using a perspex template. The tartk buffer was 0.188 M 
glycine and 25 mM Tris containing 0.1% SDS. Electrophoresis was 
run at 40 mA. After electrophoresis, gels were fixed in 45% 
methanol and 10% acetic acid until they were processed for 
fluorography.yand autoradiography or they were stained in a solution 
of 0.2% (w/v) Coomassie brilliant blue in methanol : water: acetic 
acid (9:9: 2) (v/v/v) and then destained in several changes of 
methanol : acetic acid : water (1:1:8) (v/v/v).
2.11.1. Estimation of polypeptides MW in SDS-PAGE
The MWs of electrophoresed viral polypeptides were calculated 
by the methods of Shapiro et al. (1967) and Weber and Osborn 
(1969). The labelled MW standards used were myosin (MW 200 000), 
phosphorylase B (MW 92 500), BSA (MW 69 000), ovalbumin (MW 45 000), 
carbonic anhydrase (MW 30 000) and lysozyme (MW 14 300). The 
unlabelled MW marker solution (Pharmacia Fine Chemicals, Uppsala, 
Sweden) contained the same MW standards as above except that 
myosin and lysozyme were omitted and contained trypsin inhibitor 
(MW 20 100) and ©(-lactalbumin (MW 14 400) were included. The
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distance of migration of the standards and proteins were measured, 
and a plot of the distance migrated versus the logarithm of the 
MW of the standards yielded a line from which the unknown MWs 
were calculated.
2.11.2. Autoradiography and fluorography of SDS-PAGE
Gels which contained labelled proteins were prepared for 
fluorography by the method of Bonner and Laskey (1974). After 
electrophoresis, gels were fixed in the abovementioned fixer 
solution for 16 h or more. The gels were washed in two changes 
of distilled water (30 min each) and placed in two changes of 
dimethylsulphoxide (DMSO) (Riedel de Haen, Hannover, West Germany) 
for 30 min each and then soaked for 1 h 30 min in a solution of 
DMSO containing 22% diphenyloxazole (PPO). The gels were then 
washed for 1 h with two washes of distilled water and finally 
dried on filter paper using the BIO-RAD slab dryer (BIO-RAD, CA, 
USA). Dried gels were exposed to X-ray film (Cronex-4, Du Pont 
De Nemours & Co., Inc.) in an X-ray cassette and left at -70°C 
until developed. X-ray film was developed in Adefo X-ray 
developer (Adefo-Chemie GMbH, Nurnberg, West Germany) for 5 min 
at RT and fixed in Adefo X-ray fixer for 5 min at RT. The fixed 
film was then washed in water-and air-dried.
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CHAPTER 3 
RESULTS
3.1. ESTABLISHMENT OF PERSISTENTLY INFECTED CELL LINES
3.1.1. SSPE-Vero cell line
After infecting Vero cells with the supernatant of SSPE-Vero 
cells, subcultures of the new SSPE-Vero cell lines were examined 
under light microscopy. From passage 5 (P.5) onward the cells 
formed a regular monolayer with syncitia accounting for 30 to 40% 
of the total monolayer. These cells were subcultured every four 
to five days, the rate of cell growth being faster than the 
parent Vero cell line (Fig. 4).
The new cell line was also examined by immunofluorescence 
using anti-measles antiserum. Figs. 5-8 show Vero cells before 
and after infection with SSPE. At P.l only a few cells showed 
immunofluprescence, but by P.4 the giant cells which were present 
fluoresced strongly and the immunofluorescence persisted from 
this passage onwards.
3.1.2. Sendai-Vero cell line
After infecting Vero cells with Sendai virus and subculturing 
the monolayer formed, the passages were examined by immunofluorescence 
(Figs. 9-12). The percentage of cells fluorescing when anti-Sendai 
serum was used was approximately 40 to 70% from P.16 onwards. The 
growth rate of these cells was approximately half that of the parent 
cell line (Fig. 4).
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FIG. 4. Growth curve of Vero (■-■) SSPE-Vero (•-•) and 
Sendai-Vero cells { A - A ).
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FIG. 5. Immunofluorescence of uninfected Vero cells. Cultures 
were washed in PBS, pH 7.4, fixed in cold acetone and 
stained by the indirect immunofluorescence technique 
using immune anti-measles human serum. Magnification 
1 OOOx.
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FIG. 6. Immunofluorescence of P.l SSPE-Vero cells. Cultures 
were washed in PBS, pH 7.4, fixed in cold acetone and 
stained by the indirect immunofluorescence technique 
using immune anti-measles human serum. Magnification 
1 O O O x .
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FIG. 7. Immunofluorescence of P.4 SSPE-Vero cells. Cultures 
were washed in PBS, pH 7 .4 ,  fixed in cold acetone 
and stained by the indirect immunofluorescence technique 
using anti-measles human serum. Magnification 2 OOOx.
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FIG. 8. Immunofluorescence of P.10 SSPE-Vero cells. Cultures 
were washed in PBS, pH 7.4, fixed in cold acetone and 
stained by the indirect immunofluorescence technique 
using immune anti-measles human serum. Magnification 
630x.
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FIG. 9. Immunofluorescence of P.3 Sendai-Vero cells. Cultures 
were washed in PBS, pH 7.4, fixed in cold acetone and 
stained by the indirect immunofluorescence technique 
using immune anti-Sendai mouse serum. Magnification 630x.
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FIG. 10. Immunofluorescence of P.5 Sendai-Vero cells. Cultures 
were washed in PBS, pH 7.4, fixed in cold acetone and 
stained by the indirect immunofluorescence technique 
using immune anti-Sendai mouse serum. Magnification 630x..
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FIG. 11. Immunofluorescence of P.15 Sendai-Vero cells. Cultures 
were washed in PBS, pH 7.4, fixed in cold acetone and 
stained by the indirect immunofluorescence technique 
using immune anti-Sendai mouse serum. Magnification 
630x.
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FIG. 12. Immunofluorescence of P.51 Sendai-Vero cells. Cultures 
were washed in PBS, pH 7.4, fixed in cold acetone and 
stained by the indirect immunofluorescence technique 
using immune anti-Sendai mouse serum. Magnification 630x.
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At P.36 the Sendai-Vero cell line was examined for the 
presence of viral antigen in both-the supernatant and cell 
homogenate using the HA test. While no haemagglutination 
could be found in the supernatant, the cell homogenate 
contained 15 HAU/10^ cells. Even though the HA test did not 
detect any viral antigen in the supernatant, Sendai virus was 
present as a persistent infection could be established by infecting 
Vero cells with the supernatant from Sendai-Vero cells.
3.2. IFN PRODUCTION AND ANTIVIRAL ACTIVITY
3.2.1. Endogenous IFN production
The RIA system was used to monitor the presence of endogenous 
IFN in tissue culture supernatants of each cell line used in this 
study. Monolayers of Vero cells were incubated with 100 pi of 
each cell supernatant for 24 h and then challenged with Sindbis 
virus. No cell supernatant inhibited Sindbis virus replication 
and cell lines were therefore regarded as being negative for 
endogenous IFN production. The production of IFN by Vero cells 
infected with measles or Sendai virus was also determined; no 
IFN was produced by Vero cells infected with either type of virus. 
This confirms earlier results demonstrating that Vero cells are 
unable to produce IFN (Desmyter et a 1., 1968).
3.2.2. Antiviral activity by RIA test
The sensitivity of the different cells to IFN's antiviral 
activity was determined by the RIA test. Cells were incubated
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with serial ten-fold or two-fold dilutions of IFN, or mock IFN 
for 24 h and then challenged with Sindbis virus. The sensitivity 
of the cells to IFN is given by the IFN IU/ml which inhibited 
Sindbis virus replication by 50%.
3.2.2.1. Hepatoma and CV-1 cells
Table 7 shows the sensitivity to IFN of cells infected with 
HBV or SV40 virus and the control, uninfected cell lines.
The hepatoma cells showed variable sensitivities to the anti­
viral effect of IFN as determined by the inhibition of Sindbis 
virus replication; PLC/PRF/5 and HA22T cells needed an IFN 
concentration of 2 IU/ml, Hep 3B a concentration of IFN of 4-16 
IU/ml, while the Hep G2 were the least sensitive needing an IFN 
concentration of 80 IU/ml (Table 7). No significant difference 
in the antiviral effect of IFN against Sindbis virus was found 
between hepatoma cells which produce HBsAg, PLC/PRF/5 and Hep 3B, 
and the HBsAg non-producer HA22T cell line.
Difficulties were experienced in testing the antiviral effect 
of IFN in Mahlavu cells by the RIA test; during the processes 
numerous cells were lost. The antiviral effect of IFN in these 
cells was therefore tested using the immunofluorescence assay.
Cells were pretreated with'IFN before the addition of Sindbis 
virus and the presence of Sindbis antigens determined by fluorescence 
The PLC/PRF/5 cells were also tested using the immunofluorescence 
assay so a comparison between the RIA and the immunofluorescence 
test could be made. Concentrations of 2-8 IU/ml and 8-16 IU/ml of 
IFN were needed to abolish Sindbis virus fluorescence in Mahlavu
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TABLE 7. The antiviral effect of IFN in hepatoma and CV-1 cells
CELLS IFN
(IU/ml)
PLC/PRF/5 2
HEP 3B 4-16
HA22T 2
HEP G2 80
CV-1 4
C2 4
C6 2
Cll
1
4
Cells were incubated with serial dilutions of IFN for 24 h and 
then challenged with Sindbis virus for 24 h.~ The IFN IU/ml value 
was then determined.
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and PLC/PRF/5 cells respectively indicating that Mahlavu and 
PLC/PRF/5 cells have similar sensitivities to IFN.
All CV-1 control cells and cells infected with SV40, were 
equally sensitive to the antiviral effect of IFN with sensi­
tivities of 2 to 4 IU/ml (Table 7).
Mock IFN did not inhibit Sindbis virus replication in any 
of the hepatoma and CV-1 lines used.
3.2.2.2. Cell lines persistently infected with SSPE or Sendai
virus .
Control Vero cells and Vero cells persistently infected 
with SSPE or Sendai virus were also examined for their sensitivity 
to IFN or mock IFN. A value of 4 IU/ml of IFN was able to inhibit 
Sindbis virus in Vero cells, while a value of more than or equal to 
1 600 IU/ml was required in SSPE-Vero and Sendai-Vero cell lines 
(Table 8). Mock IFN did not inhibit Sindbis virus replication in 
control Vero cells or in the two persistently infected Vero cell 
lines. These results show that there is a significant change 
regarding the sensitivity to IFN when Vero cells become persistently 
infected with either SSPE or Sendai virus.
The different passages (P.l-P.ll) obtained after infecting 
Vero cells with SSPE were examined for their sensitivity to IFN 
using the RIA test. The results are shown in Fig. 13. Control 
Vero cells were used as P.0. At P.2 a value of 4 IU/ml of IFN 
inhibited the growth of the challenge virus, while at P.5 1 600 
IU/ml of IFN was required. This shows that the loss of sensitivity
TABLE 8. The antiviral effect of IFN in uninfected Vero
cells or cells persistently infected with SSPE 
or Sendai virus
CELLS IFN
(IU/ml)
Vero 4
SSPE-Vero 1600
Sendai-Vero >1600
Cells were incubated with serial dilutions of IFN for 24 h 
and then challenged with Sindbis virus for 24 h. The IFN 
IU/ml value was then determined.
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FIG. 13. Antiviral effect of IFN at different passages of 
SSPE-Vero (#-•) or Sendai-Vero cells (■-■).
Cells were incubated with serial dilutions of IFN 
for 24 h then challenged with Sindbis virus.
Results are expressed as IFN (IU/ml) which inhibited 
Sindbis virus by 50%.
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to IFN's antiviral effect in these cells correlates with the 
percentage of fluorescence in the cells {see 3.1.1.).
Subcultures from P.l to P.22 of Vero cells infected with 
Sendai virus were also examined (Fig. 13). At P.l an IFN 
concentration of 40 IU/ml was needed to inhibit the growth of 
Sindbis virus and at P.4 an IFN concentration greater than 1600 
IU/ml was required. The development of the Sendai-Vero persistent 
infection, like the SSPE-Vero persistent infection, is characterized 
by the resistance of the cells to IFN.
3.2.3. Examination of virus specific polypeptide synthesis in 
the measlesr SSPE and Sendai systems
As SSPE-Vero and Sendai-Vero cells showed considerable 
resistance to the antiviral effect of IFN, as determined by the 
RIA assay, the effect of IFN on the synthesis of endogenous viral 
proteins was examined. The antiviral effect of IFN on measles,
SSPE and Sendai viruses was examined by RIPA followed by SDS-PAGE.
3.2.3.1. Measles-SSPE system
By the RIPA method the major measles virus polypeptides 
were readily detected, these being haemagglutinin (H), nucleo- 
protein (N), matrix (M) and proteins with approximately 50 000 MW. 
The latter proteins have been previously detected by Wechsler and 
Fields (1978). On occasion the phosphoprotein (P) was also 
detected at low levels. Cellular actin (A) was detected in most 
gels.
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Preliminary experiments were done to titrate measles virus 
by the RIPA system-and the lowest virus concentration which showed 
the presence of the major viral proteins was used in the RIPA 
experiments (Fig. 14). A virus dilution of 1.7x10 pfu/ml was 
chosen for all experiments (Fig. 14, lane 5). Extracts of cells 
infected with measles at this concentration were also reacted 
with different measles antisera to determine which antiserum 
gave the best immunoprecipitation result based on the presence 
of measles viral polypeptides. Commercial antisera and antisera 
from patients with high antibody titers were used (Figs. 15a, 15b).. 
The antiserum in lane 2 of Fig. 15b was chosen for all subsequent 
experiments.
Pretreatment of Vero cells with IFN had a significant effect 
on the synthesis of measles virus polypeptides (Fig. 16). The 
synthesis of H and N proteins was significantly reduced by 25 
IU/ml of IFN, the M protein disappeared at 50 IU/ml, and at con­
centrations greater than 200 IU/ml negligible amounts of measles 
virus proteins were detected.
The synthesis of SSPE-viral proteins was also examined, by 
RIPA, the H, and N, proteins being precipitated but not the M 
protein (Fig. 17). The lack of the M protein has been previously 
reported by Stephenson et al. (1981).
In contrast to the sensitivity of measles virus to IFN,
SSPE virus was not affected by IFN as concentrations of 4 000 
IU/ml did not inhibit the synthesis of SSPE viral proteins (Fig.17).
Mock IFN had no effect on the synthesis of either measles 
or SSPE polypeptides. The lack of an effect of mock IFN on 
measles or SSPE virus are shown in Figs. 18, 19.
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FIG. 14. Titration of measles virus polypeptides by radio-
immunoprecipitation assay (RIPA). Vero cells were
infected with dilutions of a stock culture of measles 
6virus (6.8 x 10 pfu/ml). Following labelling with 
35S-methionine, cells were harvested at 24 h p.i. and 
polypeptides analysed by RIPA. Molecular weight 
markers (MW), uninfected Vero cells (lane 1), Vero 
cells infected with measles virus (lanes 2-6), un­
diluted measles virus (lane 2), dilution 1 : 10 (lane 3), 
1 : 20 (lane 4), dilution 1 : 40 (lane 5), dilution 1 : 80 
(lane 6). Haemagglutinin (FI), nucleoprotein (N), actin 
(A), matrix (M).
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FIG. 15a. Immunoprecipitation of measles virus polypeptides
using different antisera. Human antisera (lanes 1-3, 
5-6), guinea pig antisera (lane 4).
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FIG. 15b. Immunoprecipitation of measles virus polypeptides 
using different antisera. Uninfected Vero cells 
(lane 1), human antiserum (lane 2), bovine antiserum 
(lane 3), guinea pig antiserum (lane 4), SSPE cerebral 
spinal fluid (lane 5).
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FIG. 16. Synthesis of measles virus polypeptides in the presence
or absence of IFN. Vero cells were treated with serial
dilutions of IFN for 24 h, infected with measles virus
(1.7 x 10^ pfu/ml) for 24 h then labelled with 
35S-methionine for 18 h and examined by RIPA. Uninfected 
(lane 1) or infected (lanes 2-11) cells were treated 
with EMEM alone (lanes 1, 2) or serial IFN dilutions 
(lanes 3-11).
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FIG. 17. Synthesis of SSPE virus polypeptides in the presence
or absence of IFN. SSPE-Vero cells were treated with
serial dilutions of IFN for 24 h, labelled with 
35S-methionine for 24 h then examined by RIPA. Immuno- 
precipitated measles virus proteins (lane 1), untreated 
Vero cells (lanes 2, 3), SSPE-Vero cells untreated and 
treated with serial IFN dilutions (lanes 4-13).
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FIG. 18. Synthesis of measles virus polypeptides in the
presence or absence of mock IFN. Cells were treated 
with mock IFN for 24 h, then infected with measles 
virus (1.7 x 10^ pfu/ml) for 24 h then labelled with
•3C
S-methionine for 18 h and polypeptides examined by 
RIPA. MW markers (lane 1), uninfected (lane 2) or 
infected Vero cells (lanes 3, 4), Vero cells treated 
with mock IFN (lane 4).
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FIG. 19. Synthesis of SSPE virus polypeptides in the presence
or absence of IFN or mock IFN. Cells were treated
with IFN (200 IU/ml) for 24 h, then labelled with 
35S-methionine for 24 h and polypeptides examined by 
RIPA. Untreated SSPE-Vero cells (lane 1), SSPE-Vero 
cells treated with IFN (lane 2), SSPE-Vero cells 
treated with mock IFN (lane 3).
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In sequential studies with measles virus, virus-induced 
polypeptides were detected by 12 h postinfection (p.i.) (Fig. 20), 
as previously reported by others (Wechsler and Fields, 1978).
IFN at a concentration of 200 IU/ml inhibited H, N, and M protein 
synthesis at all time intervals studied (Fig. 20). These results 
show that IFN had an inhibitory effect on measles virus poly­
peptides synthesis at all stages of the virus replication cycle.
3.2.3.2. Sendai-Vero system
With Sendai virus the major polypeptides readily distinguished 
in gels were: phosphoprotein (P), nucleocapsid (N), matrix (M) 
and proteins with MWs between 48 000-53 000. Low levels of the 
haemagglutinin (H) were sometimes detected. These proteins were 
identified according to their MWs based on the paper of Lamb et 
al_. (1976).
Sendai-Vero cells at P.30 and onwards were used to determine 
the effect of IFN on the synthesis of Sendai virus polypeptides.
As shown in Fig. 21 IFN did not inhibit the synthesis of Sendai 
virus polypeptides even at a high concentration of IFN (4 000 IU/ml).
3.3. ANTIPROLIFERATIVE ASSAYS
3.3.1. Antiproliferative effect of IFN on hepatoma and SV40 
infected cells
One of the standard methods used to assay.the antiproliferative 
effect of IFN is by measuring the incorporation of radioactive 
labeled precursors into macromolecules, such as labeled thymidine
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1 2 3 4 5 6 7 8 9 10 11 12
30 Hd
35FIG. 20. Electrophoresis of S-methionine-labelled proteins 
from Vero cells infected with measles virus after 
immunoprecipitation with measles antibody. Uninfected 
cells (lanes 3, 5, 9, 12), measles virus infected cells 
(lanes 1, 2, 4, 5, 7, 8, 10, 11), cells treated with 
IFN (200 IU/ml) (lanes 1, 3, 4, 6, 7, 9, 10, 12). 
Labelling was for 1 h from: 6 h p.i. (lanes 1-3),
12 h p.i. (lanes 4-6), 18 h p.i. (lanes 7-9), 24 h p.i. 
(lanes 10-12).
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FIG. 21. Synthesis of Sendai virus polypeptides in the presence
or absence of IFN. Sendai-Vero cells were treated
with serial dilutions of IFN for 24 h, labelled with 
35S-methionine for 24 h then examined by RIPA. Sendai- 
Vero cells untreated (lane 1), treated with IFN 
(10 IU/ml) (lane 2), IFN (100 IU/ml) (lane 3), IFN 
(1 000 IU/ml) (lane 4), IFN (4 000 IU/ml) (lane 5).
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into DNA (Hilfenhaus et al., 1976; Fuse and Kuwata, 1977;
Evinger and Pestka, 1981).
PLC/PRF/5 and Mahlavu cells were treated with different
3
concentrations of IFN and the incorporation of H-thymidine was
3
determined. IFN was able to inhibit H-thymidine incorporation 
in both cell lines with the PLC/PRF/5 cell line being more 
sensitive than the Mahlavu cell line (Fig. 22). IFN at a
3
concentration of 1 000 IU/ml inhibited H-thymidine incorporation 
by 78% in PLC/PRF/5 cells and 45% in Mahlavu cells.
3
The meaning and the interpretation of H-thymidine in­
corporation as a method of assay for the effect of IFN on cellular 
growth has lately been refuted by Gewert et al. (1981, 1983, 1984). 
These workers, in a detailed study on the incorporation of exogenous
3
H-thymidine in Daudi cells, showed that incorporation of exogenous 
tracer was not a true reflection of the effect of IFN on DNA 
synthesis and cell proliferation, and thus the method is not a 
reliable measure of the growth inhibitory activity. The anti­
proliferative effect of IFN was therefore determined by the more 
direct method of cell counting.
The IFN-induced inhibition of cell growth in hepatoma cells 
is shown in Figs. 23 and 24. The growth of the hepatoma cells, 
with the exception of the Hep 3B line, was inhibited by IFN.
Using a concentration of 1 000 IU/ml of IFN for comparative 
purposes cell growth was inhibited by 36%, 47% and 52% in HA22T, 
PLC/PRF/5 and in Hep G2 cells respectively (Figs. 23, 24), whilst 
in Mahlavu cells the level of inhibition was 19%. Mock IFN did 
not have any inhibitory effect in Hep 3B and HA22T cells while 
in PLC/PRF/5, Mahlavu and Hep G2 cells produced an inhibition of 
6%, 8% and 12% respectively (Figs. 23, 24).
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•3
FIG. 22. Inhibition of H-thymidine incorporation by IFN in
PLC/PRF/5 and Mahlavu cells. Monolayers were incubated 
with different dilutions of IFN for 48 h and then
r>
H-thymidine was added for 1 h. Incorporation was 
determined by TCA precipitation. PLC/PRF/5 (•-•), 
Mahlavu (■-■).
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FIG. 23. Antiproliferative effect of IFN on PLC/PRF/5 and
Mahlavu cells. Monolayers which were 80% confluent 
were treated with serial dilutions ofIFN for 48 h, 
harvested and counted in trypan blue. Inhibition of 
cell growth of IFN and mock IFN treated cells was 
compared with untreated controls. PLC/PRF/5 (•-•), 
Mahlavu (■-■).
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FIG. 24. Antiproliferative effect of IFN on Hep G2, HA22T and
Hep 3B cells. Monolayers were incubated with different 
dilutions of IFN for 48 h, harvested and counted in 
trypan blue. Inhibition of cell growth of IFN and 
mock IFN treated cells was compared with untreated 
controls. Hep G2 (•-•), HA22T (■-■) Hep 3B (o-o).
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By comparing the above two methods in determining the anti-
O
proliferative effect of-IFN, the inhibition of H-thymidine 
uptake would appear to be more sensitive than cell counting.
This has been previously reported by Gewert et al. (1981, 1983, 
1984), despite the fact that these authors queried the reliability 
of this method.
The antiproliferative effect of IFN on control CV-1 cells 
and CV-1 cells infected with SV40 ranged from 18 to 30% at an 
IFN concentration of 1 000 IU/ml (Fig. 25). Mock IFN did not 
have any antiproliferative effect in control CV-1 cells while in 
C2, C6 and Cll it produced an inhibition of approximately 10%.
3.3.2. Antiproliferative effect in Vero cells persistently 
infected with SSPE or Sendai virus
The results of the antiproliferative effect of IFN are shown 
in Fig. 26. IFN, at a concentration of 1 000 IU/ml inhibited 
the proliferation of Vero cells by 29%, while there was no in­
hibition of cell proliferation when SSPE or Sendai virus was 
present. Mock IFN did not produce any inhibition in the uninfec­
ted Vero cells or those persistently infected with SSPE or Sendai 
virus. Vero cells thus become significantly less sensitive to 
the antiproliferative effect of IFN when they are persistently 
infected with SSPE or Sendai virus.
3.4. E ENZYME ASSAY
All cells were assayed for E enzyme before and after treatment
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FIG. 25. Antiproliferative effect of IFN on CV-1, C2, C6 and 
Cl 1 cells. Monolayers were incubated with"different 
dilutions of IFN for 48 h, harvested and counted in 
trypan blue. Inhibition of cell growth of IFN and mock 
IFN treated cells was compared with untreated controls. 
CV-1 (#-•), C2 (o-o), C6 (■-■), Cll (□-□).
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FIG. 26. Antiproliferative effect of IFN on Vero, SSPE-Vero, 
Sendai-Vero cells. Monolayers were incubated with 
different dilutions of IFN for 48 h, harvested and 
counted in trypan blue. Inhibition of cell growth 
of IFN and mock IFN treated cells was compared with 
untreated controls. Vero (■-■), SSPE-Vero (•-•), 
Sendai-Vero (o-o).
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with IFN or mock IFN. The results are given by the amount of 
2-5 A produced during 21 h incubation with ATP adjusted to the 
protein concentration in each extract. The amount of protein 
contained in each cell extract was determined using the Bio-Rad 
protein assay kit. The amount of protein in the cell extracts 
ranged between 2 700-9 900 pg protein/ml.
3.4.1. E enzyme in hepatoma and in SV40 infected cells
Fig. 27 shows the amount of 2-5 A produced by the various 
hepatoma cells after IFN treatment. No significant difference 
in the activation of the E enzyme was seen between the two hepa­
toma cells that contain integrated HBV DNA and produce HBsAg, 
the PLC/PRF/5 and the Hep 3B cell lines, and the Mahlavu, HA22T 
and Hep G2 which do not produce HBsAg. After IFN treatment the 
level of E enzyme in the PLC/PRF/5 and Hep 3B cells increased 
from five to seven-fold compared to untreated cells while in the 
Mahlavu, HA22T, and Hep G2 cells the increase was from two to five-fold.
The CV-1 cell lines infected with SV40 showed a significant 
increase in the E enzyme level after IFN treatment (Fig. 28).
Increases of twenty-seven-fold, eighteen-fold and thirty-four­
fold were seen in C2, C6 and Cll cells respectively in comparison 
to their homologous untreated cells. An increase of six-fold 
was observed in IFN-treated control CV-1 cells (Fig. 28). The 
presence of SV40 integrated into the cell genome might be 
responsible for making the CV-1 cells very sensitive to the IFN- 
mediated induction of E enzyme.
The effect of mock IFN in stimulating the E enzyme varied
PLC|PRF|5 HEP3B MAHLAVU HA22T HEPG2
FIG. 27. Histograms of E enzyme levels (2-5 A pmoles/h/pg 
protein) in extracts of hepatoma cells untreated 
(1), treated with IFN (200 IU/ml) (2), treated with 
mock IFN (3).
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FIG. 28. Histograms of E enzyme levels (2-5 A pmoles/h/pg
protein) in extracts of CV-1, C2, C6 and Cll cells 
untreated (1), treated with IFN (200 Ili/ml) (2), 
treated with mock IFN (3).
between hepatoma and CV-1 cell lines but the level of E enzyme 
induced was always considerably lower than that induced by IFN 
(Figs. 27, 28).
3.4.2. E enzyme in Vero cells infected with SSPE or Sendai virus
Uninfected Vero cells showed an eighteen-fold increase in the 
E enzyme level after IFN treatment, while Vero cells persistently 
infected with Sendai virus had a very low basal level of the E 
enzyme and the enzyme increased by only 1.8-fold after IFN 
treatment (Fig. 29). An increase of nine-fold of the E enzyme 
level after IFN treatment was seen in SSPE-Vero cells, but this 
increase is regarded as being insignificant considering the very 
low basal level of the enzyme in this cell line (Fig. 29). In the 
Vero and SSPE-Vero cell lines mock IFN increased the level of 
the E enzyme only very slightly.
The development of persistent infections in the Vero cells 
was followed using the E enzyme assay. As is shown in Fig. 30,
IFN1s ability to induce the E enzyme was significantly reduced 
when the Vero cells became persistently infected with SSPE or 
Sendai virus.
3.5. RIBONUCLEASE F ASSAY
Hovanessian and Wood (1980) have previously shown that 
activation of the ribonuclease F could be measured by the addition 
of exogenous 2-5 A to cells. 2-5 A is introduced into the cells 
by CaCl2 coprecipitation and is responsible for activating the
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FIG. 29. Histograms of E enzyme levels (2-5 A pmoles/h/pg
protein) in extracts of Vero, SSPE-Vero, Sendai-Vero 
cells. Untreated cells (1), treated with IFN 
(200 IU/ml) (2), mock IFN (3).
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FIG. 30. Histograms of E enzyme levels (2-5 A pmoles/h/pg 
protein) in extracts of different passages of 
SSPE-Vero and Sendai-Vero cells. Untreated cells (1), 
treated with IFN (200 IU/ml) (2).
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ribonuclease F, which in turn degrades mRNA and rRNA (Baglioni 
et al., 1978; Nilsen et al., 1980). By stimulating the degrada­
tion of RNA, 2-5 A is indirectly responsible for the inhibition 
of protein synthesis and this inhibition can be measured by the
3
incorporation of H-leucine.
Each cell line was assayed for ribonuclease F activity at
3
least three times and the percentage of H-leucine incorporation 
was determined. A ribonuclease F positive cell line, L-cells 
(Panet et al., 1981), and a negative ribonuclease F cell line, 
NIH-3T3 (Panet et al., 1981) were also tested and used as controls 
(Fig. 31). Inhibition of 61% and 14% can be seen in L and 
NIH-3T3 cells respectively at 10~6M of 2-5 A.
3.5.1. Ribonuclease F in hepatoma and SV40 infected cells
The three hepatoma cell lines, PLC/PRF/5, Hep 3B and Hep 62, 
were largely insensitive to the addition of 2-5 A with a maximum
o
10% inhibition of H-leucine incorporation in the PLC/PRF/5 
cells with a concentration of 10“Sl of 2-5 A (Fig. 32). To 
check if an increase in the activation of the ribonuclease F 
could be seen, these three cell lines were pretreated with rec 
o<-IFN (200 IU/ml) for 24 h before the 2-5 A was added. The ribo­
nuclease F activity after IFN treatment did not increase in 
PLC/PRF/5 or Hep G2 cells, while in Hep 3B cells pretreated with 
IFN a concentration of 10"Sl of 2-5 A produced an inhibition of
3
H-leucine incorporation of 19%, equal to an increase of 2.7-fold 
in comparison to Hep 3B cells non-treated with IFN. HA22T and 
Mahlavu cells were sensitive to 2-5 A with a maximum of 56% and
100
3FIG. 31. Effect of 2-5 A on H-leucine Incorporation in L and 
NIH-3T3 cells. Monolayer cells were treated with 
serial dilutions of 2-5 A in transfection buffer 
containing CaCl9 for 135 min. Medium was changed and 
after 105 min H-leucine was added for 1 h. Incorporation 
was determined by TCA precipitation. L-cells (•-#), 
NIH-3T3 cells (■-■).
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FIG. 32. Effect of 2-5 A on 3H-leucine incorporation in
hepatoma cell lines. Monolayers were treated with
serial dilutions of 2-5 A in transfection buffer
containing CaCl~ for 135 min. Medium was changed 
C 3and after 105 min H-leucine was added for 1 h. 
Incorporation was determined by TCA precipitation. 
PLC/PRF/5 (•-•), Hep 3B (o-o), Mahlavu (■-■), 
HA22T (□-□), Hep G2 ( a -a ) cells.
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35% inhibition respectively when a similar concentration of 
10~Sl of 2-5 A was used {Fig. 32).
An investigation was done to find out if the reason for the 
lack of sensitivity to 2-5 A in PLC/PRF/5 hepatoma cell line 
was caused by a reduced uptake of 2-5 A. The ribonuclease 
positive, Mahlavu, and the ribonuclease negative, PLC/PRF/5, 
cell lines were compared in their ability in incorporating 
2-5 A.
The permeability of the hepatoma cells to the transfection 
buffer was first studied using trypan blue uptake and then by 
incorporation of labelled 2-5 A. No differences in permeability 
were found between PLC/PRF/5 and Mahlavu cell lines using trypan 
blue; in fact 90% of both these hepatoma cell lines were 
permeable when transfection buffer contained CaCl2, whereas only 
2% were permeable when CaCl2 was omitted. The percentage of 
labelled 2-5 A incorporated by the cells was then calculated.
In the presence of CaCl2 the PLC/PRF/5 cells incorporated 34% 
of the labelled 2-5 A and the Mahlavu cells 30% whereas in the 
absence of CaCl2 an incorporation of approximately 4% was observed 
in both cell lines (Table 9).
From these results it can be concluded that the lack of 
ribonuclease F activity in PLC/PRF/5 cells was not due to a 
defect of 2-5 A uptake but might be due to some intracellular 
defect.
3
2-5 A significantly inhibited the incorporation of H-leucine 
in CV-1 control cells and CV-1 infected with SV40 with a maximum 
of inhibition between 67 to 83% at lCfSl of 2-5 A (Fig. 33).
These results show that both the CV-1 control and C2, C6, and Cll
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TABLE 9. Uptake of labelled 2-5 A by the PLC/PRF/5 and 
Mahlavu cells
CELLS TREATMENT % LABELLED 2-5 A
PLC/PRF/5
-CaCl2 4
+CaCl2 34
MAHLAVU
-CaCl2 4
+CflC12 30
Monolayers were treated with labelled 2-5 A in transfection buffer 
in the presence or absence of CaCl2 for 45 min and the amount of 
labelled 2-5 A present at 45 min compared to 0 min is given as a 
percentage. The mean of three experiments is given.
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FIG. 33. Effect of 2-5 A on 3H-leucine incorporation in CV-1,
C2, C6 and Cll cells. Monolayers were treated with 
serial dilutions of 2-5 A in transfection buffer 
containing CaCl9 for 135 min. Medium was changed and 
after 105 min H-leucine was added for 1 h. Incorporation 
was determined by TCA precipitation. CV-1 (•-•),
C2 (o-o), C6 (■-■), Cll (□-□) cells.
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cell lines are sensitive to 2-5 A and that they have an endogenous 
ribonuclease F enzyme.
3.5.2. Ribonuclease F in Vero persistently infected with 
SSPE or Sendai virus
Vero, SSPE-Vero and Sendai-Vero cell lines responded positiv­
ely to 2-5 A as is shown by a similar decrease in the rate of
3 3H-leucine incorporation (Fig. 34). Incorporation of H-leucine
was inhibited by 79% on Vero cells, 84% in SSPE-Vero cells, and
65% in Sendai-Vero cells.
3.6. PROTEIN KINASE
Stimulation of the protein kinase by IFN was assayed using 
the enzyme's ability to phosphorylate the oC-subunit of eIF-2 as 
the phosphorylation of the endogenous PI (69 000 MW) could not 
readily be detected due to strong background in this region of 
the gels. Murine L-cells were used as a positive control as 
these cells have been shown to activate the protein kinase (Zilber- 
stein et al., 1976). These cells were treated with muIFN or 
mouse mock IFN, while all the other cells were treated with 
lymphoblastoid IFN.
Extract of cells before or after IFN treatment were reacted 
with exogenous eIF-2. Two samples of eIF-2 were used (see 
Materials and Methods) and their purity compared by SDS-PA6E 
(Fig. 35). This figure shows that both samples of eIF-2 contain 
the oC-subunit and are contaminated with the £ -subunit (50 000 MW);
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3FIG. 34. Effect of 2-5 A on H-leucine incorporation in Vero,
SSPE-Vero and Sendai-Vero cells. Monolayers were
treated with serial dilutions of 2-5 A in transfection
buffer containing CaCl, for 135 min. Medium was
^ 3changed and after 105 min H-leucine was added for 1 h. 
Incorporation was determined by TCA precipitation.
Vero (■-■), SSPE-Vero (o-o), Sendai-Vero (•-•) cells.
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FIG. 35. Electrophoresis of eIF-2 preparations used. Gels
were stained with Coomassie blue. Batch B (lane 1), 
Batch A (lane 2).
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the phosphorylation of the jjj-subunit appeared in most gels when 
eIF-2 was added and this has been previously reported by Samuel (1979b).
The L-cells were reacted with the two different samples of 
eIF-2 (Figs. 36, 37). The ©(-subunit in each sample of eIF-2 
was phosphorylated to the same extent by the L-cell extracts.
In sample B a contaminant with a MW of 33 000 was present (Fig.
37). This contaminant which was previously seen (Palomo et al.,
1985), runs very close to the <5(-eIF-2 protein which, in some 
instances, made the results difficult to interpret. The two 
eIF-2 samples were titrated in the protein kinase system; the 
titration of sample A is shown in Fig. 38.
As seen in Figs. 36 and 37 the activation of the protein 
kinase by IFN could be confirmed by the phosphorylation of the 
endogenous PI (67 000 MW). The latter protein appeared phos­
phorylated every time an extract of L-cells treated with muIFN 
was assayed in the presence of dsRNA.
3.6.1. Protein kinase in hepatoma cell lines and SV40 infected 
cells
Extracts of PLC/PRF/5 and Mahlavu cells were tested using 
sample A of eIF-2 and no increase in phosphorylation of c(-eIF-2 
was observed after IFN treatment (Figs. 39, 40). Extracts of Hep 3B, 
Hep 62 and HA22T cells were tested with sample B of eIF-2. In the 
Hep 3B cell extract no increase in phosphorylation of «<-eIF-2 
could be observed after IFN treatment as the same level of phos­
phorylation is seen before treatment (Fig. 41 lanes 7, 12) and for 
this reason IFN was considered unable to activate the protein 
kinase in Hep 3B cells. Extracts of Hep 62 and HA22T cells,
109
1 2 3 4 5 6 7 8
IFN - - - - + + + +
ds RNA - + — + - + _ |
e-IF2 - - + + - - + +
9 10 11 12
+ + + + 
-  +  -  +  
-  - + +
1
3 0 -
FIG. 36. Autoradiogram showing the effect of IFN on the protein 
phosphorylation of L-cells. L-cell extracts from 
cells treated in the presence or absence of IFN were 
incubated for 30 min in the presence or absence of 
dsRNA (1 pg/ml), eIF-2 (2 jjg) (Batch A) in buffer 
containing ATP-^P. The extracts were then resuspended 
in dissociation buffer, run on SDS-PAGE and the gel 
fluorographed. Untreated cells (lanes 1-4), treated 
with muIFN (200 IU/ml) (lanes 5-8), treated with mock 
IFN (lanes 9-12).
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FIG. 37. Autoradiogram showing the effect of IFN on the protein 
phosphorylation of L-cells. L-cell extracts from cells 
treated in the presence or absence of muIFN were 
incubated for 30 min in the presence or absence of 
dsRNA (1 fjg/ml), eIF-2 (2 pg) (Batch B) in buffer 
containing ATP-^P. The extracts were then resuspended 
in dissociation buffer, run on SDS-PAGE and the gel 
fluorographed. Untreated cells (lanes 1-4), treated 
with muIFN (lanes 5-8).
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FIG. 38. Autoradiogram of extracts of L-cells pretreated with
muIFN (200 IU/ml) and then incubated in the presence
of different concentrations of eIF-2. Extracts were
incubated for 30 min in the presence of dsRNA (1 pg/ml),
of different concentrations of eIF-2 (Batch A) in
32buffer containing ATP- P. The extracts were then 
resuspended in dissociation buffer, run on SDS-PAGE 
and the gel fluorographed. Treated with eIF-2 (5 pg) 
(lane 1), eIF-2 (2.5 pg) (lane 2), eIF-2 (2 pg) (lane 3) 
without eIF-2 (lanes 4, 5). The presence of * and 
R -eIF-2 are indicated.
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FIG. 39. Autoradiogram showing the effect of IFN on the protein 
phosphorylation of extracts of PLC/PRF/5 cells.
Extracts from cells treated in the presence or absence 
of IFN (200 IU/ml) were incubated for 30 min in the
presence or absence of dsRNA (1 pg/ml), of eIF-2 (2 ug)
32  '(Batch A) in buffer containing ATP- P. The extracts 
were then resuspended in dissociation buffer, run on 
SDS-PAGE and the gel fluorographed. L-cell extracts 
(lanes 1-4), PLC/PRF/5 cell extracts (lanes 5-12).
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FIG. 40. Autoradiogram showing the effect of IFN on the protein 
phosphorylation of extracts of Mahlavu cells. Extracts 
from cells treated in the presence or absence of IFN 
(200 IU/ml) were incubated for 30 min in the presence 
or absence of dsRNA (1 jjg/ml), of eIF-2 (2 jjg) (Batch A) 
in buffer containing ATP-^P. The extracts were then 
resuspended in dissociation buffer, run on SDS-PAGE 
and the gel fluorographed. L-cell extracts (lanes 1-4), 
Mahlavu cell extracts (lanes 5-12).
114
1 2 3 4 5  6  7 8 9 10 i i 12
IF N  + 4- + 4- — — — - +■ +> + 4-
d s R N A - + - + -  +  — +■ -  + - +
e IF 2 - + 4- -  -  + + -  - 4- 4-
FIG. 41. Autoradiogram showing the effect of IFN on the protein 
phosphorylation of extracts of Hep 3B cells. Extracts 
from cells treated in the presence or absence of IFN 
(200 IU/ml) were incubated for 30 min in the presence
or absence of dsRNA (1 |jg/ml), of eIF-2 (2 }jg) (Batch B)
3?in buffer containing ATP-' P. The extracts were then 
resuspended in dissociation buffer, run on SDS-PAGE 
and the gel fluorographed. L-cell extracts (lanes 
1-4), Hep 3B cell extracts (lanes 5-12).
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as well, did not increase the phosphorylation of the °(-eIF-2 
after IFN treatment (Fig. 42).
All CV-1 cell extracts, uninfected and infected with SV40, 
were tested with sample B of eIF-2 and did not show any increase 
in phosphorylation of (X-eIF-2 after IFN treatment (Figs. 43-45). 
It appears that the protein kinase system is not used by the 
hepatoma and CV-1 cells.
3.6.2. Protein kinase in Vero cells infected with SSPE or 
Sendai virus
Vero and SSPE-Vero cell extracts were tested with sample 
A of eIF-2. In Vero cells «<-eIF-2 was phosphorylated, but no 
increase in phosphorylation was seen after IFN treatment, while 
in SSPE-Vero cells no phosphorylation of c(-eIF-2 was found 
(Figs. 46, 47).
Vero and Sendai-Vero cell extracts were subsequently tested 
using sample B of eIF-2 and in both cell extracts *(-eIF-2 was 
phosphorylated before and after IFN treatment. No increase in 
the phosphorylation could be seen after IFN treatment or in the 
presence of dsRNA (Fig. 48). Sendai-Vero extracts were also run 
in parallel with L-cells (Fig. 49). These results show that 
as in the Vero cells, in Sendai-Vero the protein kinase stimulated 
by IFN is not activated.
3.7. SUMMARY
The summary of the results of the experiments done in this 
thesis are shown in Table 10.
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FIG. 42. Autoradiogram'showing the effect of IFN on the protein 
phosphorylation of extracts of Hep G2 and HA22T cells. 
Extracts from cells treated in the presence or absence 
of IFN (200 IU/ml) were incubated for 30 min in the
presence or absence of dsRNA (1 ug/ml), of eIF-2 (2 fjg)
* 32(Batch B) in buffer containing ATP- P. The extracts 
were then resuspended in dissociation buffer, run on 
SDS-PAGE and the gel fluorographed. Hep G2 cell 
extracts (A), HA22T cell extracts (B). L-cell extract 
(lane 9).
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FIG. 43. Autoradiogram showing the effect of IFN on the
protein phosphorylation of extracts of CV-1 cells. 
Extracts from cells treated in the presence or 
absence of IFN (200 IU/ml) were incubated for 30 min 
in the presence or absence of dsRNA (1 |jg/ml), of eIF-2 
(2 fjg) (Batch B) in buffer containing ATP-^P. The 
extracts were then resuspended in dissociation buffer, 
run on SDS-PAGE and the gel fluorographed. L-cell 
extracts (lanes 1-4), CV-1 cell extracts (lanes 5-12).
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FIG. 44-. Autoradiogram showing the effect of IFN on the protein 
phosphorylation of extracts of C2, C6 cells. Extracts 
from cells treated in the presence or absence of IFN 
(200 IU/ml) were incubated for 30 min in the presence 
or absence of dsRNA (1 fjg/ml), of eIF-2 (2 Ug) (Batch B) 
in buffer containing ATP-‘^P. The extracts were then 
resuspended in dissociation buffer, run on SDS-PAGE 
and the gel fluorographed. C2 cell extracts (A), C6 
cell extracts (B), L-cell extracts (lane 9).
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FIG. 45. Autoradiogram showing the effect of IFN on the protein 
phosphorylation of extracts of Cll cells. Extracts 
from cells treated in the presence or absence of IFN 
(200 IU/ml) were incubated for 30 min in the presence 
or absence of dsRNA (1 pg/ml), of eIF-2 (2 jug) (Batch B) 
in buffer containing ATP-^P. The extracts were then 
resuspended in dissociation buffer, run on SDS-PAGE 
and the gel fluorographed. L-cell extracts (lanes 
1-4), Cll cell extracts (lanes 5-12).
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FIG. 46. Autoradiogram showing the effect of IFN on the protein
phosphorylation of extracts of Vero cells. Extracts
from cells treated in the presence or absence of IFN
(200 IU/ml) were incubated for 30 min in the presence
or absence of dsRNA (1 (jg/ml), of eIF-2 (2 i^g) (Batch .A)
3 2in buffer containing ATP-' P. The extracts were then 
resuspended in dissociation buffer, run on SDS-PAGE 
and the gel fluorographed. L-cell extracts (lanes 1-4), 
Vero cell extracts (lanes 5-12).
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FIG. 47. Autoradiogram showing the effect of IFN on the protein 
phosphorylation of extracts ofSSPE-Vero cells. Extracts 
from cells treated in the presence or absence of IFN 
(200 IU/ml) were incubated for 30 min in the presence 
or absence of dsRNA (1 pg/ml), eIF-2 (2 pg) (Batch A) 
in buffer containing ATP-32P. The extracts were then 
resuspended in dissociation buffer, run on SDS-PAGE 
and the gel fluorographed. L-cell extracts (lanes 1-4), 
SSPE-Vero cell extracts (lanes 5-12).
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FIG. 48. Autoradiogram showing the effect of IFN on the protein
phosphorylation of extracts of Vero and Sendai-Vero cells. 
Extracts from cells treated in the presence or absence 
of IFN (200 IU/ml) were incubated for 30 min in the 
presence or absence of dsRNA (1 pg/ml), eIF-2 (2 pg) 
(Batch B) in buffer containing ATP-^P. The extracts 
were then resuspended in dissociation buffer, run on 
SDS-PAGE and the gel fluorographed. Vero cell extracts 
(A), Sendai-Vero cell extracts (B).
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FIG. 49. Autoradiogram showing the effect of IFN on the protein
phosphorylation of extracts of Sendai-Vero cells.
Extracts from cells treated in the presence or absence
of IFN (200 IU/ml) were incubated for 30 min in the
presence or absence of dsRNA (1 Lig/ml), eIF-2 (2 ug)
1 32(Batch B) in buffer containing ATP- P. The extracts 
were then resuspended in dissociation buffer, run on 
SDS-PAGE and the gel fluorographed. Sendai-Vero cell 
extracts (A), L-cell extracts (B).
TABLE 10. Summary of results of IFN's assays in the cell lines used in this thesis
ANTIVIRAL ^ ANTI- (b) E ENZYME ACTIVATION ^ RIBONUCLEASE F (d) PROTEIN KINASE (e)
(RIA) 
IFN IU/ml
PROLIFERATIVE
-IFN +IFN
ACTIVATION ACTIVATION
PLC/PRF/5 2 47 0.31 2.35 10 -
HEP 3B 4-16 0 0.32 1.76 7 -
MAHLAVU 2-8 * 19 0.24 1.06 35 -
HA22T 2 36 0.28 1.36 56 -
HEP G2 80 52 0.86 1.7 7 -
CV-1
|
4 • 30 0.28 1.72 83 -
C2 4 18 0.39 10.6 76 -
C6 2 24 0.20 3.74 67 -
Cll 4 29 0.27 10.35 78 -
VERO 4 29 0.35 6.3 79 -
SSPE-VERO 1600 0 0.02 0.19 84 -
SENDAI-VERO 1600 0 0.05 0.09 65 -
(a) concentration of IFN which inhibits Sindbis virus replication by 50%
(b) % inhibition of cell growth after treatment with 1 000 IU/ml of IFN
(c) pmoles of 2-5 A/h/pg protein produced before and after IFN (200 IU/ml)
(d) % inhibition of 3H-ieucine incorporation after addition of 2-5 A lO-^M
(e) phosphorylation of added pv-eIF-2
•k determined by immunofluorescence
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CHAPTER 4 
DISCUSSION
Many viruses from a wide variety of families have evolved 
strategies whereby they can persist in a host without destroying 
it. In virology the term "persistence" is used with remarkable 
looseness to cover a wide variety of situations which could not 
conceivably be grouped together under any single, properly 
defined heading (Epstein, 1982).
A recent appraisal of virus persistence is the paper by Mahy 
(1985) in which he divided persistence into that occurring in the 
individual and that occurring in the cell.
Regarding persistence in the individual, he defined three 
mechanisms which are listed below; however, it is important to 
point out that these are not distinct groupings, as for example, 
mechanisms 1 and 3 are both exhibited by a number of virus groups. 
The mechanisms are:
1) integration into cellular DNA
2) latent infection of neuronal cells
3) persistent infection with virus shedding
A virus family for which genome integration into cellular 
DNA is well documented as a means of persistent infection is the 
Retroviridae (Topp et al., 1981). One retrovirus subfamily, the 
lentiviruses, is of particular interest. Examples in this subfamily 
are Visna and Equine Infectious Anaemia (EIA) viruses (Youngner 
and Preble, 1980; Stroop and Baringer, 1982). Visna virus 
produces a slow progressive disease in sheep affecting the central
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nervous system (Gudnadottir, 1974) while EIA infects horses and 
produces immunological-mediated lesions (Henson and McGuire, 1974).
In both viruses infection can persist for many years despite the 
host immune response. It is clear that the mechanism of persistence 
in these two viruses involves integration of viral DNA into the 
host genome and antigenic variation (Mahy, 1985). As these 
lentiviruses also produce periodic viraemia they could be classi­
fied in the third group of persistent infection.
Haase et al. (1977) have found high levels of Visna DNA, low 
levels of viral RNA and no virus in sheep choroid plexus during 
persistent infection. This suggests that viral DNA is maintained 
in cells in vivo but that the expression of viral genetic information 
is blocked at the transcriptional level. Therefore the infected 
cells do not express viral antigens and are not recognized as 
foreign by the host immune system (Stroop and Baringer, 1982).
Another way in which Visna and EIA viruses can persist is 
by mutations of the major envelope glycoprotein. These mutations 
are responsible for the production of antigenic variants which 
enable the virus to circumvent the host immune response (Narayan 
et al., 1977; Stroop and Baringer, 1982). The latter phenomenon 
has been termed antigenic drift (Youngner and Preble, 1980).
The Herpesviruses are the best example of latent infection 
of neuronal cells. These viruses, after producing a primary 
infection, can persist in a latent state for the host's lifetime 
(Mahy, 1985).
Herpesviruses most commonly establish a persistent infection 
in the central nervous system by infecting the spinal ganglia 
(Stevens and Cook, 1971). Virus reactivation may occur when the
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virus migrates along the peripheral nerve fibre of a tissue 
(ter Meulen et al., 1984). No expression of viral antigens in 
latently infected ganglion cells has been found, suggesting 
that in this way the virus avoids the host immune defence 
mechanism (Stroop and Baringer, 1982).
Whether the Herpesvirus DNA is in the integrated or episomal 
form is still uncertain (Rock and Fraser, 1983; Mahy, 1985). 
Herpes virus DNA can be detected in latently infected tissue by 
hybridization, but little or no virus specific RNA can be found 
(Galloway et al., 1982;’ Rock and Fraser, 1983).
The third type of persistent infection in humans and animals 
is characterized by the recovery of the virus or parts of the 
virus in the serum and tissue throughout the life of the host 
(Mahy, 1985). Two examples of this type of persistent infection 
are HBV and measles virus. After a primary infection with HBV, 
4-5% of the cases become disease carriers and a proportion of • 
these carriers continue to shed infectious virus and maintain 
significant levels of HBsAg in their sera (Szmuness, 1975; 
Zuckerman, 1975)..,
HBV virus DNA may become integrated iinto the liver cell 
genome (Shafritz et al., 1981) and these integrated HBV sequences 
often remain after all forms of episomal DNA have disappeared 
(Mason et al., 1985). The integration of HBV DNA into the cell 
genome preferentially uses a single stranded region of the viral 
genome and is probably random (Koshy et al., 1983). Integrated 
sequences often contain multiple deletions, inversions and/or 
duplications and rearrangements have been detected in flanking 
cellular sequences (Koch et al., 1984). Based on these facts it
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is clear that HBV also falls into the first group defined by 
Mahy (1985), that of integration of virus into the cellular 
genome.
Measles virus infection, after causing a primary disease 
may lead to a complication of the central nervous system, 
termed subacute sclerosis panencephalitis (SSPE), which only 
appears a few years later (Wechsler and Meissner, 1982). High 
levels of measles antibody occur in the serum and the cerebro­
spinal fluid of patients with SSPE (Connolly et al., 1967). No 
detectable extracellular viral particles are found in the brain 
(Dubois-Dalcq, 1979); however the virus can be recovered from 
the brain cells by cocultivation with cells permissive for 
measles virus (Wechsler and Meissner, 1982). The mechanism of 
measles virus persistence in SSPE is not completely understood, 
but it seems that a defect in expression of the virus matrix 
protein in infected brain cells may prevent the formation of 
mature viral particles (Hall and Choppin, 1979). Other factors 
may be related to the persistent measles infection such as the 
accumulation of large numbers of nucleocapsids in the nuclei of 
SSPE infected brain cells rather than in the cytoplasm (Dubois- 
Dalcq, 1979). In latent infections the nucleocapsid has also 
been shown, in electron micrographs, to have a smooth appearance 
as opposed to the fuzzy appearance observed in acute measles 
infection; also, they do not align with the cell membrane and 
no budding virus has been observed in brain cells (Dubois-Dalcq,
1979). The theory of antigenic modulation has also been put 
forward as a cause of persistent measles infection (Joseph and 
Oldstone, 1975). In the latter case measles virus antibody may
strip or modulate viral antigens from the surface of infected 
cells, thus protecting the cells from immunological injury 
(Joseph and Oldstone, 1975)*
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Mahy (1985) has defined four mechanisms whereby viruses 
persist at the cellular level. These mechanisms, which have 
been studied in vitro, are:
1) carrier culture
2) steady-state infection
3) intracytoplasmic persistence
4) latent infection
In carrier cultures only a small proportion of the cell 
population is infected. The infected cells release virus and 
die and the virus then infects only a small proportion of the 
remaining cells (Mahy, 1985). An example of a carrier culture 
infection is lymphocytic choriomeningitis virus which in L-cells 
shows regular fluctuations in the amount of virus released into 
the medium (Weber et al., 1983; Lehman-Grube et al., 1983).
The second type of in-vitro persistent infection is the 
steady-state infection where both virus and cell multiplication 
are in equilibrium (Mahy, 1985). This equilibrium probably 
involves both viral and cellular genetic factors. Many RNA 
viruses produce a persistent steady-state infection by the selection 
of mutants which are less cytopathic (Youngner and Preble, 1980).
Examples of virus mutants such as DI and ts mutants are 
numerous (Rima and Martin, 1976; Holland et al., 1980; Youngner 
and Preble, 1980). The evolution of measles and Sendai virus 
mutants which replicate in cells without a significant cytopathic
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effect has been studied in several cell lines (Youngner and Preble,
1980). A decrease in the level of expression of the haemagglutinin 
and matrix proteins has been observed in many cellular systems 
(Roux and Waldvogel, 1982, 1983; Giraudon et al., 1984; Roux 
et al., 1984; Sheshberadaran et al., 1985).
The third type of in-vitro persistent infection termed 
intracytoplasmic persistence has only been observed with lympho­
cytic choriomeningitis virus in C13/SV28 and in BHK-21F cells 
(Mahy, 1985). In this case the medium of the infected cells did 
not contain any virus or DI particles (van der Zeijst et al., 1983). 
In-vitro infection can be established using virus-infected cell 
extracts or by cell-cell contact; the infectious material is 
probably contained in large vesicles (van der Zeijst et al., 1983).
The fourth type of in-vitro persistent infection defined by 
Mahy (1985) is a true latent infection where the viral genome or 
part of the genome is integrated into the host cell genome. This 
type of persistent infection is usually established by retroviruses 
and DNA viruses (Mahy, 1985). Examples of retroviruses that 
establish such latent infections are EIA and Visna viruses (Cheevers 
et al., 1982), while examples of DNA viruses are HBV and SV40 
(Marion et al., 1980; Topp et al., 1981; Twist et al., 1981).
Integrated DNA viruses have been shown to be responsible for 
the transformation of cells and for the induction of cancer 
(Grodzicker and Hopkins, 1981; Hadziyannis, 1980). In most cell 
lines transformed with SV40 or infected with HBV the presence of 
integrated viral DNA is evident by the continuous production of 
viral proteins such as T antigen and HBsAg (Grodzicker and Hopkins, 
1981; Koshy et al., 1981).
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SV40 can become integrated into the cellular genome at 
several sites and this integration is stable for many generations 
(Topp et al., 1981). Virus specific RNA has been found in both 
SV40 transformed cell lines as well as in the hepatoma PLC/PRF/5 
cells (Chakraborty et al., 1980; Topp et al., 1981). No episomal 
HBV DNA has been found in PLC/PRF/5 or Hep 3B cells and while 
transformed SV40 cells may or may not contain free copies of 
viral DNA they can contain single or multiple copies of integrated 
DNA and may also contain either less than one whole genome or 
tandem duplicated copies (Marion et al., 1980; Twist et al.,
1981; Griffin, 1982).
In this study five cell lines derived from primary liver 
carcinoma were examined. Two cell lines containing HBV DNA were 
compared with three control cell lines which did not contain 
HBV DNA. The ability of IFN to inhibit the replication of an 
exogenous virus, to stimulate the antiproliferative effect and to 
activate the two IFN-induced enzymes was examined.
The characteristics of the hepatoma cell lines used have 
been previously studied. All these hepatoma cell lines produced 
the characteristic liver enzymes and hepatocyte plasma proteins 
(Hammond et al., 1975; Alexander et al., 1976; Aden et al.,
1979; Knowles et al., 1980; Chang et al., 1983). o<-fetoprotein 
was produced by the Hep G2, Hep 3B and by the PLC/PRF/5 cells 
while all the hepatoma cell lines, except Hep G2, produced tumours 
in mice (Bassedine et al., 1980; ODaemer et al., 1980; Sattler 
et al., 1982; Shouval et al., 1981, 1985; Chang et al., 1983). 
Hep G2 was the only cell line that was derived from an hepato­
blastoma (Knowles et al., 1980). The cell structure of most of
the hepatoma cells is polygonal and only the Mahlavu cells have 
a fibroblast-like morphology. HBsAg is produced by the Hep 3B 
and PLC/PRF/5 cells and both these cell lines had HBV DNA integrated 
into the cellular genome (Macnab et al., 1976; Oefinger et al., 
1981; Aden et al., 1979; Koshy et al., 1981; Twist et al.,
1981; Ziemer et al., 1985).
The sensitivity to IFN has only been studied previously in 
the PLC/PRF/5 cells (Desmyter et al., 1981; Nakajima et al.,
1982) and their results correlated with those obtained in this 
study:
1) PLC/PRF/5 cells did not produce IFN constitutively.
2) After IFN treatment PLC/PRF/5 cells could inhibit 
exogenous RNA virus replication at low levels of IFN 
such as 2 IU/ml (Table 7).
3) After IFN treatment the level of endogenous E enzyme 
increased (Fig. 27)-
4) IFN produced an antiproliferative effect in PLC/PRF/5 
cells (Figs. 22, 23).
Desmyter et al. (1981) showed as well that PLC/PRF/5 cells were 
unable to induce IFN when they were challenged with Newcastle 
disease virus or with poly(l)poly(C), a synthetic IFN inducer.
IFN could not inhibit the formation of tumours in mice injected 
with PLC/PRF/5 cells, and could not stop the production of HBsAg 
in PLC/PRF/5 cells (Desmyter et al., 1981; Nakajima et al.,
1982). In conclusion, IFN could not inhibit the synthesis of 
HBV products such as HBsAg or the development of hepatocellular 
carcinoma, but could prevent the replication of exogenous virus
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and stimulate an antiproliferative effect.
In this thesis it was also shown that IFN did not induce 
either the ribonuclease F or the protein kinase in the PLC/PRF/5 
cells. The sensitivities of the other hepatoma cell lines to 
IFN did not always follow the same pattern as the PLC/PRF/5 cell 
line although similarities were found. In all the hepatoma cells 
studied no endogenous IFN could be detected in cell supernatants. 
Variable sensitivity to the antiviral effect of IFN against 
Sindbis virus was found (Table 7), the least sensitive being Hep 
G2 cells which needed an IFN concentration of 80 IU/ml to inhibit 
Sindbis virus replication. In general, low amounts of IFN could 
inhibit Sindbis virus replication in hepatoma cells and there 
was no difference with the control HBsAg non-producer cell lines.
IFN did not induce the protein kinase in any hepatoma cell line 
studied as shown in Figs. 39-42. However the E enzyme was activated 
in all the hepatoma cell lines after IFN treatment (Fig. 27); in 
PLC/PRF/5 and Hep 3B cells the level of E enzyme increased 
approximately six-fold while an increase of approximately four­
fold was seen in the control Mahlavu and HA22T cells. The level of 
E enzyme in the Hep G2 cells reached a level equal to that of the 
Hep 3B cells, but their basal level, i.e. before stimulation, was 
much higher than the basal level of E enzyme in the Hep 3B cells.
In fact, Hep G2 cells had the highest basal level of all the 
hepatoma cell lines and an increase of only two-fold in the E 
enzyme level was seen after IFN treatment (Fig. 27).
The ability of the hepatoma cell lines to respond to the 
activation of the ribonuclease F, the second enzyme activated in 
the E enzyme pathway, was studied by measuring the inhibition
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of H leucine incorporation after exogenous 2-5 A had been 
introduced into the cells. In Hep 3B, PLC/PRF/5 cells and in 
Hep 62 cells, 2-5 A was unable to activate the ribonuclease F, 
while in Mahlavu and HA22T cells the ribonuclease F was activated 
(Fig. 32). Pretreatment of PLC/PRF/5 and Hep 62 with rec *(-IFN 
(200 IU/ml) did not increase the ribonuclease F level while with 
Hep 3B cells there was a partial activation of the enzyme as
3
shown by a 2.7-fold decrease in H-leucine incorporation at 
10'^M of 2-5 A. The lack of activation of the ribonuclease F in 
PLC/PRF/5 cells was not caused by an inability to introduce 2-5 
A into the cells as the same amount of 2-5 A was introduced into 
these cells as in the Mahlavu cells (Table 9).
The antiproliferative effect of IFN on hepatoma cells showed 
that the growth of all the hepatoma cells studied with the 
exception of the Hep 3B cells could be inhibited (Figs. 22-24). 
The sensitivity of the different hepatoma cell lines to the anti­
proliferative effect varied as Mahlavu cells reacted to a lesser 
extent than the PLC/PRF/5, HA22T or the Hep 62 cells.
It therefore appears that the PLC/PRF/5 and the Hep 62 cell 
lines use neither the protein kinase nor the second part of the 
E enzyme pathway to inhibit virus replication, whereas the 
Mahlavu, the HA22T and possibly Hep 3B cells could use the E 
enzyme pathway as both the E enzyme and the ribonuclease F are 
activated. However, as Sindbis virus replication is inhibited 
in all hepatoma cell lines following IFN treatment (Table 7) 
and as IFN induces an antiproliferative effect in all hepatoma 
cell lines, with the exception of Hep 3B cells (Figs. 22-24), 
indicates that there might be other pathway(s) available whereby
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IFN acts. These results also show that there is no distinct 
correlation between the induction of the two main IFN-enzyme 
systems and the presence of integrated HBV DNA.
The results with Hep 3B cells where there is activation of 
the antiviral effect but no activation of the antiproliferative 
effect show that there must be two distinct and dissociable 
intracellular pathways whereby IFN affects its antiviral and anti­
proliferative actions as previously proposed by Taylor- 
Papadimitriou et al. (1985).
The other DNA virus system that was studied was the persistent 
infection of CV-1 cells with SV40 virus. SV40 virus is a papova- 
virus which has been shown to produce tumours when it is injected 
into newborn hamsters (Eddy et al., 1962; Girardi et al., 1962) 
and to transform cells (Todaro and Green, 1964; Black, 1966).
In SV40-transformed cells IFN has been shown to be unable to 
inhibit the synthesis of the early T antigen, but inhibits the 
replication of exogenous VSV and the production of T antigen 
in a superinfection with SV40 (Oxman et al., 1967; Revel, 1979; 
Garcia-Bianco et al♦, 1985). The inability of IFN to inhibit 
the production of SV40 T antigen in SV40-transformed cells is 
similar to the inability of IFN to prevent the production of 
HBsAg in hepatoma derived cell lines containing integrated HBV 
DNA. This lack of IFN's effect may be due to the fact that IFN 
does not recognise viral mRNA as the viral DNA in both cases is 
integrated into the cell genome (Revel, 1979; Nakajima et al., 
1982).
Three SV40-transformed cell lines, C2, C6 and Cll, were 
used in this study. All three cell lines produce SV40 T antigen
and have the growth characteristics of a non-permissive trans­
formed cell line such as reduced cell density inhibition, reduced 
serum dependence, ability to overgrow normal cells and colony 
formation in soft agar (Gluzman et al., 1977; Prives et al.,
1978). No spontaneous release of infectious virus occurs however, 
and SV40 DNA is integrated in these cell lines (Gluzman et al.,
1977; Prives et al., 1978). Each cell line has a single 
incomplete insert of viral DNA sequence and the bulk of the SV40 
sequences are associated with the high molecular weight chromosomal 
DNA (Gluzman et al., 1977; Krieg et al., 1981). Restriction 
mapping of the inserted SV40 DNA indicated that the early viral 
DNA region is.retained in all cells and alterations are found 
in the late regions (Krieg et al., 1981).
CV-1 cells were used as controls and the effects of IFN on 
CV-1, C2, C6 and Cl1 cells were compared. Neither CV-1 control 
nor infected cells spontaneously secreted IFN, but all were 
sensitive to the antiviral effect of IFN (Table 7) with a low 
concentration of IFN (2-4 IU/ml) inhibiting replication. All 
control and infected cells were sensitive to the antiproliferative 
effect of IFN with 30% inhibition of cell growth at an IFN 
concentration of 1 000 IU/ml (Fig. 25). As with most of the 
hepatoma cells, IFN was able to activate the antiviral and anti­
proliferative pathways.
The stimulation of the E enzyme after IFN treatment (200 IU/ml) 
was six-fold in the control CV-1 cells (Fig. 28) while a significantly 
higher increase in the level of E enzyme after IFN treatment was 
seen in C2, C6 and Cll cells. The presence of ribonuclease F in 
CV-1, C2, C6 and Cll cells was shown by a significant decrease in the
incorporation of H-leucine after introduction of 2-5 A (Fig. 33). 
These results indicate that both the E enzyme and ribonuclease F 
are active in the SV40-infected cells, and therefore this pathway 
is functioning in these cells. A large increase in the synthesis 
of 2-5 A in cells pretreated with IFN and then infected with 
SV40 has previously been reported (Revel et al., 1980; Hersh 
et al., 1984). However, Hersh et al. (1984) have analysed by 
high performance liquid chromatography the 2-5 A products and 
have found that most of these products were largely non-functional 
2-5 A cores or non-phosphorylated 2-5 A and that these products 
were unable to activate the ribonuclease F or to degrade rRNA 
and virus RNA. It is possible that the 2-5 A produced in the C2, 
C6 and Cll cells examined in this study also contained a large 
percentage of non-functional 2-5 A. The protein kinase was not 
stimulated in any of the CV-1 cells uninfected or infected with 
SV40 virus (Figs. 43-45).
The presence of SV40 appears to significantly increase the 
level of E enzyme following IFN treatment and presuming that the 
2-5 A produced is functional and the fact that the ribonuclease F 
is induced, would indicate that this pathway is active.
The effect of IFN on persistent RNA virus infections was 
studied in SSPE and Sendai viruses.
In this study the effect of IFN on a Vero cell line 
persistently infected with SSPE was compared with the uninfected 
Vero cell line. Vero cells have previously been shown to be 
unable to produce IFN (Desmyter et al., 1968) and the presence 
of measles or SSPE virus in the cells did not change this
3
characteristic.
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Very low levels of IFN (4 IU/ml) inhibited Sindbis virus 
replication in Vero cells while a concentration of 1 600 IU/ml 
of IFN was needed to inhibit Sindbis virus replication in SSPE- 
Vero cells; this represents a 400-fold decrease in the sensitivity 
of SSPE-Vero to IFN. A possible reason for this decreased 
sensitivity was investigated by examining the ability of IFN to 
activate the E enzyme and protein kinase pathways. Protein 
kinase was not induced in either the Vero or SSPE-Vero cells 
(Figs. 46-47), while there was decreased activation of E enzyme 
in SSPE-Vero cells as compared to the control Vero cells (Fig. 29). 
SSPE-Vero cells also had a very low basal level of E enzyme, 
which was approximately ten times lower than the uninfected Vero 
cells (Table 10). Thus a major difference between the two cell 
lines would appear to be the level to which the E enzyme was 
activated. The second part of the E enzyme pathway in both Vero 
and SSPE-Vero cells could be activated as shown by inhibition of
3
the incorporation of H-leucine by approximately 80% after 2-5 A 
was introduced into the cells.
SSPE-Vero cells were not only less sensitive to the anti­
viral effect of IFN but were also less sensitive to the anti­
proliferative effect of IFN when compared to the control Vero 
cells. In fact, no inhibition on cell growth in SSPE-Vero cells 
was found while Vero cells were inhibited by 30% at an IFN 
concentration of 1 000 IU/ml (Fig. 26).
As SSPE-Vero cells produce SSPE virus, a new Vero cell line 
persistently infected with SSPE was established. Passages from 
P.l onwards were examined for their sensitivity to IFN. While 
early passages were sensitive to the antiviral effects of IFN 
and the levels of E enzyme induced were similar to control Vero
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cells (Fig. 30) by P.4 the cells needed a 400-fold greater 
concentration of IFN to inhibit Sindbis-virus replication. At 
P.4 large syncitia were present and these showed strong viral 
immunofluorescence in the cytoplasm. The E enzyme level determined 
at P.7 v*as very low following IFN treatment (Fig. 30).
The effect of IFN on the synthesis of measles and SSPE 
viral proteins was also examined in this study. While an IFN 
concentration of 25 IU/ml inhibited the synthesis of measles H 
and N proteins and by 50 IU/ml the M protein had disappeared 
(Fig. 16), a concentration of 4 000 IU/ml of IFN did not inhibit 
the synthesis of any SSPE viral proteins (Fig. 17). The effect 
of IFN in inhibiting measles polypeptide synthesis was present 
from the beginning of the replication cycle (Fig. 20).
From these results it can be concluded that the actions of 
IFN are considerably reduced in SSPE-Vero cells, with IFN having 
negligible antiviral and antiproliferative effects. It is most 
likely that this decreased sensitivity to IFN is due to the 
presence of SSPE virus. The fact that the E enzyme is induced 
in these cells, albeit at a very low level, would indicate that 
IFN does have a slight activity in stimulating at least one of 
its antiviral pathways.
The other persistent RNA virus infection examined was Sendai 
virus. As' with measles virus, Sendai virus is a good inducer of 
IFN in lymphoblastoid cells and IFN reduces cytolysis in HeLa 
cells infected with Sendai virus (Finter and Fantes, 1980; Sato 
et al., 1980).
A monolayer of Vero cells was infected with Sendai virus 
and a persistent infection was obtained by subculturing the
colonies that survived the lytic effect of Sendai virus. The new 
colonies established a monolayer which had the morphology of 
Vero cells and more than 50 sequential subcultures have been 
done with continuous presence of viral antigens. Immunofluorescence 
showed that 50% of these cells were infected with Sendai virus.
No IFN could be detected in the culture media, but low levels of 
virus were produced as the culture media could induce a persistent 
infection in Vero cells. Absence of IFN in the medium of HeLa 
cells persistently infected with Sendai virus (HVJ-strain) has 
been reported (Maeno et al., 1966).
An IFN concentration of more than 1 600 IU/ml was needed 
to inhibit the replication of Sindbis virus in this newly 
established Sendai-Vero cell line; this is at least a 400-fold 
higher concentration than the one needed in Vero cells. Ito et 
al. (1979) have also found a decreased sensitivity to the anti­
viral effect of IFN in Vero cells persistently infected with 
HVJ Sendai.
The activation of the main enzymes induced by IFN was 
examined. The level of E enzyme was only increased 1.8 fold 
and the protein kinase was not activated (Figs. 29, 48, 49). As 
with SSPE-Vero cells the basal level of endogenous E enzyme was 
lower than in the control Vero cells (Table 10). The Sendai- 
Vero cell line was sensitive to the action of 2-5 A as there was 
activation of the ribonuclease F enzyme. Similar activation of 
the ribonuclease F was seen in control Vero cells (Fig. 34).
No antiproliferative effect of IFN in the Sendai-Vero cells 
was seen at an IFN concentration of 1 000 IU/ml (Fig. 26).
The effect of IFN on endogenous Sendai virus protein synthesis 
in these persistently infected Vero cells was also studied. No
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inhibition of the synthesis of the Sendai virus protein P, H, or 
N, was detected even at 4 000 IU/ml of IFN (Fig. 21). It can 
thus be concluded that the antiviral and antiproliferative actions 
of IFN in Sendai-Vero cells are considerably reduced in comparison 
to the control Vero cells. Therefore, as with SSPE-Vero cells, 
a persistent infection with Sendai virus changes the sensitivity 
of Vero cells to IFN.
CONCLUSIONS
The results of this thesis show that there are major differences 
between the two persistent DNA virus infections and the RNA virus 
infections studied as regards to their sensitivity to IFN. The 
presence of integrated HBV or SV40 genomes had no significant 
effect on the antiviral and antiproliferative effects of IFN and 
generally these cell lines were as sensitive to IFN as their 
controls. This indicates that this type of persistent infection 
does not significantly modify the overall IFN mechanism in these 
cells. It is interesting to note that in the hepatoma cell lines 
in particular the two main IFN enzyme pathways are induced to a 
variable extent. In none was the protein kinase activated while 
there was variable activation of the E enzyme. The activation of 
these two enzyme pathways has been regarded as the main mechanism 
involved in the antiviral effect of IFN (Torrence, 1982), but 
the lack of correlation between the IFN-mediated antiviral state 
and the two enzyme pathways has been previously reported (Verhaegen 
et al., 1980; Hovanessian et al., 1981; Meurs et al., 1981).
Cell lines which are sensitive to the antiviral effect of IFN
but do not stimulate both enzyme pathways have been reported 
(Meurs et al., 1981; Holmes and Gupta, 1982; Sen et al7, 1983).
The significance of the results of these workers and those 
obtained in this thesis is that the IFN mediated antiviral effect 
is not always dependent in the activation of the E enzyme or 
the protein kinase pathways. The intracellular events leading 
to the development of the antiviral response may vary not only 
from one cell system to the other (Hovanessian et al., 1981;
Meurs et a 1., 1981), but also from virus to virus (Samuel and 
Knutson, 1981; Tomita et al., 1982b). The involvement of 
another pathway in providing an IFN-antiviral effect can then 
be suggested.
In contrast to the two DNA virus persistent infections, the 
presence of RNA viruses such as SSPE or Sendai viruses altered 
dramatically the sensitivity of a cell line to IFN. This change 
was evident within a few passages in the development of persistence, 
and was characterised by a significant decrease in the anti­
proliferative and antiviral effects of IFN. This shows that in 
this type of persistent infection, the presence of the RNA virus 
somehow alters the cell's response to IFN. As the E enzyme was 
induced to a slight extent in both cell lines this would indicate 
that IFN had some minimal action. It is possible that in these 
persistent infections the presence of the virus affects the 
initial action of IFN, feasible propositions being a reduction 
in the number of IFN receptors on the cell membrane or a block 
in some messages after IFN's entry into the cell. This would 
therefore render the cell insensitive to IFN.
Further investigation into the exact mechanism of this
phenomenon is important as abolition of IFN's antiviral effect, 
one of the major defence mechanisms of the host, may be important 
in the establishment of persistent infections caused by RNA 
viruses such as measles. Measles virus has been implicated not 
only as the cause of SSPE but also multiple sclerosis and 
Paget's diseases (Rebel et al., 1980; Haase et al., 1981;
Basle et al., 1985). A decreased sensitivity to IFN may be a 
common theme in the development of these three diseases and 
also of other chronic degenerative diseases of unknown etiology.
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